1 L.4.5.2 Adipsin expression in mice 1092
1.1 L.1.0.1 General considerations
Influence of the central nervous system, in particular of the hypothalamus, on development of obesity has been suspected since the early clinical observations of Babinski (1900) and Fröhlich (1901), Biedl 1916). Experiments reported by Smith (1927, 1930) showed that injections of chromic acid into the suprasellular region of rats with lesion of the hypothalamus induced obesity in rats (Bomskov 1939). Hetherington and Ranson (1939) found that electrolytic lesions, restricted to the ventromedial region of the hypothalamus, could be associated with the development of obesity.
A virally induced obesity syndrome in mice was described by Lyons et al. (1982).
Chan (1995) gave a review on β-cell stimulus-secretion coupling defects in rodent models of obesity.
Leiter and Herberg (1997) reviewed the advances in understanding the molecular bases for monogenic obesity mutations capable of producing obesity-induced...
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
References
Astrup A, Lundsgaard C (1998) What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinic practice. Exp Clin Endocrinol Diabetes 106, Suppl 2:29–34
Babinski MJ (1900) Tumeur de corps pituitaire sans acromegalie et avec manquer de developpement des organes genitaux. Rev Neurol 8:531–533
Biedl A (1916) Innere Sekretion. Ihre physiologischen Grundlagen und ihre Bedeutung für die Pathologie. Zweiter Teil. Urban und Schwarzenberg, Berlin/Wien, pp 173–179
Bomskov C (1939) Methodik der Hormonforschung, Zweiter Band, Georg Thieme Verlag Leipzig, pp 614–615
Bray G, York DA (1979) Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. Physiol Rev 59:719–809
Chan CB (1995) β-Cell stimulus-secretion coupling defects in rodent models of obesity. Can J Physiol Pharmacol 73:1414–1424
Fröhlich A (1901) Ein Fall von Tumor der Hypophysis cerebri ohne Akromegalie. Wien Klin Rundsch 15:883–886
Hetherington AW, Ranson SW (1939) Experimental hypothalamico-hypophyseal obesity in the rat. Proc Soc Exp Biol Med 41:465–466
Leiter EH, Herberg (1997) The polygenetics of diabesity in mice. Diabetes Rev 5:131–148
Lyons MJ, Faust IM, Hemmes RB, Buskirk DR, Hirsch J, Zabriskie JB (1982) A virally induced obesity syndrome in mice. Science 216:82–85
Scalfani A (1984) Animal models of obesity: classification and characterization. Int J Obesity 8:491–508
Smith PE (1927) The disabilities caused by hypophysectomy and their repair. The tuberal (hypothalamic) syndrome in the rat. J Amer Med Assoc 88:158–161
Smith (1930) Amer J Anat 45:265
References
Collins S, Daniel KW, Petro AE, Surwit RS (1997) Strain-specific response to β3-adrenergic receptor agonist treatment of diet-induced obesity in mice. Endocrinology 138:405–413
Folch J, Lees M, Sloane-Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissue. J Biol Chem 226:497–509
Foster DO, Ma SWY (1989) The effector of diet-induced thermogenesis: brown adipose tissue or liver? In: Lardy H, Stratman F (eds) Hormones, Thermogenesis and Obesity. Elsevier, New York, pp 165–171
Harris RB (1993) The impact of high-or low-fat cafeteria foods on nutrient intake and growth of rats consuming a diet containing 30% energy as fat. Int J Obes 17:307–315
Herberg L, Döppen W, Major E, Gries FA (1974) Dietary-induced hypertrophic-hyperplastic obesity in mice. J Lipid Res 15:580–585
Hill JO, Lin D, Yakubu F, Peters JC (1992) Development of dietary obesity in rats: influence of amount and composition of dietary fat. Int J Obes 16:321–333
Hirsch J, Gallian E (1968) Methods for determination of adipose cell size in man and animals. J Lipid Res 9:110–119
LeBlanc J, Labrie A (1997) A possible role for palatability of the food in diet-induced thermogenesis. Int J Obes 21:1100–1103
Llado I, Pons A, Palou A (1997) Fatty acid composition of brown adipose tissue in dietary obese rats. Biochem Mol Biol Int 43:1129–1136
Levin BE, Dunn-Meynell AA, Balkan B, Keesey R (1997) Selective breeding for diet-induced obesity and resistance in Sprague-Dawley rats. Am J Physiol (Regul Integr Comp Physiol) 273:R725–R730
Mayer J (1953) Genetic, traumatic and environmental factors in the etiology of obesity. Physiol Rev 33:472–508
Rolls BJ, Rowe RA, Turner RC (1980) Persistent obesity in rats following a period of consumption of a mixed, high energy diet. J Physiol 298:415–427
Rothwell NJ, Stock MJ (1986) Brown adipose tissue and diet-induced thermogenesis. In: Trayhum P, Nicholls DG (eds) Brown Adipose Tissue. Edward Arnold, Ltd., London, pp 269–298
Rothwell NJ, Saville ME, Stock MJ (1982) Effects of feeding a “cafeteria” diet on energy balance and diet-induced thermogenesis in four strains of rats. J Nutr 112:1515–1524
Salmon DMV, Flatt JP (1985) Effect of dietary fat content on the incidence of obesity among ad libitum fed mice. Int J Obes 9:443–449
Scalfani A, Springer D (1976) Dietary obesity in adult rats: similarities to hypothalamic and human obesity syndromes. Physiol Behav 17:461–471
Segues T, Salvado J, Arola L, Alemany M (1994) Long-term effects of cafeteria diet feeding on young Wistar rats. Biochem Mol Biol Int 33:321–328
Stock MJ, Rothwell NJ (1979) Energy balance in reversible obesity. In: Festing MFW (ed) Animal Model of Obesity. MacMillan Press Ltd., pp 141–151
Tiscari J, Nauss-Karol C, Levin BE, Sullivan AC (1985) Changes in lipid metabolism in diet-induced obesity. Metabolism 34:580–587
Wade GN, Gray JM (1979) Gonadal effects on food intake and adiposity: a metabolic hypothesis. Physiol Behav 22:583–593
West DB, Boozer CN, Moody DL, Atkinson RL (1992) Dietary obesity in nine inbred mouse strains. Am J Physiol 262:R1025–R1032
West DB; Waguespack J, York B, Goudey-Lefevre J, Price RA (1994) Genetics of dietary obesity in AKR/J x RWR/J mice: segregation of the trait and identification of a linked locus on chromosome 4. Mammalian Genome 5:546–552
References
Bray GA, York DA (1979) Hypothalamic and genetic obesity in experimental animals: An autonomic and endocrine hypothesis. Physiol Rev 59:719–809
Elmquist JK, Elias CF, Saper CB (1999) From lesions to leptin: Hypothalamic control of food intake and body weight. Neuron 22:221–232
Funahashi T, Shimomura I, Hiraoka H, Arai T, Takahashi M, Nakamura T, Nokazi S, Yamashita S, Takemura K, Tokonuga K, Matsusawa Y (1995) Enhanced expression of rat obese (ob) gene in adipose tissue of ventromedial hypothalamus (VMH)-lesioned rats. Biochem Biophys Res Commun 211:469–475
Gold RM, Kapatos G, Carey RJ (1973) A retracting wire knife for stereotaxic brain surgery made from a microliter syringe. Physiol Behav 10:813–815
Himms-Hagen J, Tokuyama K, Eley J, Park IRA, Cui J, Zaror-Behrens G, Coscina DV (1989) Hypothalamic regulation of brown adipose tissue in lean and obese rodents. In: Lardy H, Stratman F (eds) Hormones, Thermogenesis and Obesity. Elsevier, New York, pp 173–184
Leibowitz SF, Hammer NJ, Chang K (1981) Hypothalamic paraventricular nucleus lesions produce overeating and obesity in the rat. Physiol Behav 27:1031–1040
Liu CM, Yin TH (1974) Caloric compensation to gastric loads in rats with hypothalamic hyperphagia. Physiol Behav 13:231–238
Sclafani A, Aravich PF (1983) Macronutrient self-selection in three forms of hypothalamic obesity. Am J Physiol (Regul Integr Comp Physiol 13):R686–694
Vander Tuig, Kerner J, Romsos DR (1985) Hypothalamic obesity, brown adipose tissue, and sympathoadrenal activity in rats. Am J Physiol 248 (Endocrinol Metab 11):E607–E617
References
Brecher G, Waxler SH (1949) Obesity in albino mice due to single injections of goldthioglucose. Proc Soc Exp Biol Med 70:498–501
Debons AF, Silver L, Cronkite EP, Johnson A, Brecher G, Tenzer D, Schwartz IL (1962) Localization of gold in mouse brain in relation to gold thioglucose obesity. Am J Physiol 202:743–750
Debons AF, Krimsky I, Likuski HJ, From A, Cloutier RJ (1968) Goldthioglucose damage to the satiety center: inhibition in diabetes. Am J Physiol 214:562–658
Debons AF, Krimsky I, Maayan ML, Fani K, Jimenez FA (1977) Goldthioglucose obesity syndrome. Fed Proc 36:143–137
Deter RL, Liebelt RA (1964) Goldthioglucose as an experimental tool. Texas Rep Biol Med 22:229–243
Laughton W, Powley TL (1981) Bipiperidyl mustard produces brain lesions and obesity in the rat. Brain Res 221:415–420
Marshall NB, Barrnett RJ, Mayer J (1955) Hypothalamic lesions in goldthioglucose injected mice. Proc Soc Exp Biol Med 90:240–244
Mizutani T (1977) Characterization of obesity in mice induced with 4-nitroquinoline 1-oxide. Jap J Vet Sci 39:141–147
Perry JH, Liebelt RA (1961) Extra-hypothalamic lesions associated with gold-thioglucose induced obesity. Proc Soc Exp Biol Med 106:55–57
Rutman RJ, Lewis FS, Bloomer WD (1966) Bipiperidyl mustard, a new obesifying agent in the mouse. Science 153:1000–1002
Smith CJV (1972) Hypothalamic glucoreceptors — the influence of gold thioglucose implants in the ventromedial and lateral hypothalamic areas of normal and diabetic rats. Physiol Behav 9:391–396
Smith CJV, Britt DL (1971) Obesity in the rat induced by hypothalamic implants of gold thioglucose. Physiol Behav 7:7–10
Stauffacher W, Lambert AE; Vecchio D, Renold AE (1967) Measurement of insulin activities in pancreas and serum of mice with spontaneous (“obese” and “New Zealand obese”) and induced (goldthioglucose) obesity and hyperglycemia, with considerations on the pathogenesis of the spontaneous syndrome. Diabetologia 3:230–237
References
Bunyan D, Merrell EA, Shah PD (1976) The induction of obesity in rodents by means of monosodium glutamate. Br J Nutr 35:25–39
Olney JW (1969) Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 164:719–721
Pizzi WJ, Barnhart JE (1976) Effects of monosodium glutamate on somatic development, obesity and activity in the mouse. Pharmacol Biochem Behav 5:551–557
Poon TKY, Cameron DP (1978) Measurement of oxygen consumption and locomotor activity in monosodium glutamate-induced obesity. Am J Physiol 234:E532–E534
Redding TW, Schally AV, Arimura A, Wakabayashi I (1971) Effect of monosodium glutamate on some endocrine functions. Neuroendocrinology 8:245–255
Remke H, Wilsdorf A, Müller F (1988) Development of hypothalamic obesity in rats. Exp Pathol 33:223–232
Seress L (1982) Divergent effects of acute and chronic monosodium L-glutamate treatment on the anterior and posterior parts of the arcuate nucleus. Neuroscience 7:2207–2216
Tokuyama K, Himms-Hagen J (1986) Brown adipose tissue thermogenesis, torpor, and obesity in glutamate-treated mice. Am J Physiol 251 (Endocrin Metab 14):E407–E415
Yoshida T, Nishioka H, Nakamura Y, Kondo M (1984) Reduced norepinephrine turnover in mice with monosodium glutamate-induced obesity. Metabolism 33:1060–1063
Yoshida T, Nishioka H, Nakamura Y, Kanatsuna T, Kondo M (1985) Reduced norepinephrine turnover in brown adipose tissue of pre-obese mice treated with monosodium-L-glutamate. Life Sci 36:931–938
Yoshida T, Sakane N, Wakabayashi Y, Umekawa T, Kondo M (1994) Anti-obesity effect of CL 316,243, a highly specific β3-adrenoceptor agonist, in mice with monosodium-L-glutamate-induced obesity. Eur J Endocrinol 131:97–102
References
Bray GA, York DA (1979) Hypothalamic and genetic obesity in experimental animals: An autonomic and endocrine hypothesis. Physiol Rev 59:719–809
Cawthorne (1979) The use of animal models in the detection and evaluation of compounds for the treatment of obesity. In: Festing MFW (ed) Animal Model of Obesity. MacMillan Press Ltd., pp 79–90
Coleman DL (1978) Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice
Festing MFW (1979) The inheritance of obesity in animal models of obesity. In Festing MFW (ed) Animal Model of Obesity. MacMillan Press Ltd., pp 15–37
Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395:763–770
Hunt CE, Lindsey JR, Walkley SU (1976) Animal models of diabetes and obesity including PBB-Ld mouse. Fed Proc 35:1206–1217
Westman S (1968) Development of the obese-hyperglycaemic syndrome in mice. Diabetologia 4:141–149
References
Koizumi M, Shimoda I, Sato K, Shishido T, Ono T, Ishizuka J, Toyota T, Goto Y (1989) Effects of CAMOSTAT on development of spontaneous diabetes in the WBN/Kob rats. Biomed Res 10, Suppl 1:45–50
Nakama K, Shichinohe K, Kobayashi K, Naito K, Ushida O, Yasuhara K, Zobe M (1985) Spontaneous diabetes-like syndrome in WBN/Kob rats. Acta Diabetol Lat. 122:335–342
Tsichitani M Saegusa T, Narama I, Nishikawa T, Gonda T (1985) A new diabetic strain of rat (WBN/Kob) Laboratory Animals 19:200–207
Abadie JM, Wright B, Correa G, Browne ES, Porter JR, Svec F (1993) Effect of dihydro-epiandrosterone on neurotransmitter levels and appetite regulation of the obese Zucker rat. Diabetes 42:662–669
Alamzadeh R, Slonim AE, Zdanowicz MM (1993) Modification of insulin resistance by diazoxide in obese Zucker rats. Endocrinology 133:705–712
Bray GA (1977) The Zucker-fatty rat: A review. Fed Proc 36:148–153
Cleary MP (1989) Antiobesity effect of dehydroepiandrosterone in the Zucker rat. In: Lardy H, Stratman F (eds) Hormones, Thermogenesis and Obesity. Elsevier, New York, pp 365–376
Clark JB, Palmer CJ, Shaw WN (1983) The diabetic Zucker fatty rat. Proc Soc Exp Biol Med 173:68–75
Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H (1988) Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549–1558
Galante P, Maerker E, Scholz R, Rett K, Herberg L, Mosthaf L, Häring HU (1994) Insulin-induced translocation of GLUT 4 in skeletal muscle of insulin-resistant Zucker rats. Diabetologia 37:3–9
Kasim SE, Elovson J, Khilnani S, Almario RU, Jen KLC (1993) Effect of lovostatin on the secretion of very low density lipoproteins and apolipoprotein B in the hypertriglyceridemic Zucker obese rat. Atherosclerosis 104:147–152
Kava R, Greenwoof MRC, Johnson PR (1990) Zucker (fa/fa) rat. Ilar News 32:4–8
Lynch CJ, McCall KM, Billingsley ML, Bohlen LM, Hreniuk SP, Martin LF, Witters LA, Vannucci SJ (1992) Pyruvate carboxylase in genetic obesity. Am J Physiol 262 (Endocrinol Metab 25):E608–618
McCaleb ML, Sredy J (1992) Metabolic abnormalities of the hyperglycemic obese Zucker rat. Metabolism 41:522–525
Rouru J, Pesonen U, Isaksson K, Huupponen R, Koulu M (1993) Effect of chronic treatment with TFMPP, a 5-HT1 receptor agonist, on food intake, weight gain, plasma insulin and neuropeptide Y mRNA expression in obese Zucker rats. Eur J Pharmacol 234:191–198
Santti E, Huupponen R, Rouro J, Hänninen V, Pesonen U, Jhanwar-Uniyal M, Koulu M (1994) Potentiation of the anti-obesity effect of the β3-adrenoceptor agonist BRL 35135 in obese Zucker rats by exercise. Br J Pharmacol 113:1231–1236
Savontaus E, Raasmaja A, Rouru J, Koulu M, Pesonen U, Virtanen R, Savola JM, Huupponen R (1997) Anti-obesity effect of MPV-1743 A III, a novel imidazoline derivative, in genetic obesity. Eur J Pharmacol 328:207–215
Shafrir E (1992) Animal models of non-insulin-dependent diabetes. Diabetes/Metab Rev 8:179–208
Triscari J, Sullivan AC (1987) A pharmacotherapeutic approach to the regulation of hyperinsulinemia and obesity. Int J Obesity 11, Suppl 3:43–51
Truett GE, Bahary N, Friedman JM, Leibel RL (1991) Rat obesity gene fatty (fa) maps to chromosome 5: Evidence for homology with the mouse gene diabetes (db). Proc Natl Acad Sci USA 88:7806–7809
Vasselli JR, Flory T, Fried KS (1987) Insulin binding and glucose transport in adipocytes of acarbose-treated Zucker lean and obese rats. Int J Obesity 11:71–75
Yoshioka S, Nishino H, Shiraki T, Ikeda K, Koike H, Okuno A, Wada M, Fujiwara T, Horikoshi H (1993) Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 42:75–80
Zhang B, Graziano MF, Doebber TW, Leibowitz MD, White-Carrington S, Szalkowski DM, Hey PJ, Wu M, Cullinan CA, Bailey P, Lollmann B, Frederich R, Flier JS, Strader CD, Smith RG (1996) Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem 271:9455–9459
Zucker LM (1965) Hereditary obesity in the rat associated with hyperlipidemia. Ann NY Acad Sci 131:447–458
Ikeda H, Shino A, Matsuo T, Iwatsuka H, Suzuoki Z (1981) A new genetically obese-hyperglycemic rat (Wistar fatty). Diabetes 30:1045–1050
Kava R, Peterson RG, West DB, Greenwood MRC (1990) Ilar News 32:9–13
Kava RA, West DB, Lukasik VA, Greenwood MRC (1989) Sexual dimorphism of hyperglycemia and glucose tolerance in Wistar fatty rats. Diabetes 38:159–163
Kobayashi M, Iwanshi M, Egawa K, Shigeta Y (1992) Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes 41:476–483
Madar Z, Omusky Z (1991) Inhibition of intestinal α-glucosidase activity and postprandial hyperglycemia by α-glucosidase inhibitors in fa/fa rats. Nutrit Res 11:1035–1046
Mazusaki H, Hosoda K, Ogawa Y, Shigemoto M, Satoh N, Mori K, Tamura N, Nishi S, Yoshimasa Y, Yamori Y, Nakao K (1996) Augmented expression of obese (ob) gene during the process of obesity in genetically obese-hyperglycemic Wistar fatty (fa/fa) rats. FEBS Lett 378:267–271
Peterson RG, Little LA, Neel MA (1990) WKY fatty rat as a model of obesity and non-insulin dependent diabetes mellitus. Ilar News 32:13–15
Velasquez MT, Kimmel PL, Michaelis OE,IV (1990) Animal models of spontaneous diabetic kidney disease. FASEB J 4:2850–2859
Aizawa T, Taguchi N, Sato Y, Nakabayashi T, Kobuchi H, Hidaka H, Nagasawa T, Ishihara F, Itoh N, Hashizume K (1995) Prophylaxis of genetically determined diabetes by diazoxide: a study in a rat model of naturally occurring obese diabetes. J Pharmacol Exp Ther 275:194–199
Ishida K, Mizuno A, Sano T, Shima K (1995) Which is the primary etiologic event in Otsuka Long-Evans Tokushima fatty rats, a model of spontaneous non-insulin-dependent diabetes mellitus, insulin resistance, or impaired insulin secretion? Metabolism 44:940–945
Kawano K, Hirashima T, Mori S, Kurosumi M, Saitoh Y (1991) A new rat strain with non-insulin dependent diabetes mellitus, “OLETF”. Rat News Lett 25:24–26
Kawano K, Hirashima T, Mori S, Saitoh YA, Kurosumi M, Natori T (1992) Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima fatty (OLETF) strain. Diabetes 41:1422–1428
Umekawa T, Yoshida T, Sakane N, Saito M, Kumamoto K (1997) Anti-obesity and anti-diabetic effects of CL316,243, a highly specific β3-adrenoceptor agonist, in Otsuka Long Evans Tokushima Fatty rats: induction of uncoupling protein and activation of glucose transporter 4 in white fat. Eur J Endocrinol 136:429–437
Yamamoto M, Dong M J, Fukumitsu KI, Imoto I, Kihara Y, Hirohata Y, Otsuki M (1999) Metabolic abnormalities in the genetically obese and diabetic Otsuka Long Evans Tukushima fatty rat can be prevented by α-glucosidase inhibitor. Metab Clin Exp 48:347–354
Emsberger P, Koletsky RJ, Friedman JE (1999) Molecular pathology in the obese spontaneous hypertensive Koletsky rat: A model of syndrome X. Ann New York Acad Sci 892:272–288
Koletsky S (1973) Obese spontaneous hypertensive rats-a model for study of arteriosclerosis. Exp Mol Pathol 19:53–60
Koletsky S (1975) Pathologic findings and laboratory data in a new strain of obese hypertensive rats. Am J Pathol 80:129–142
Russell JC, Graham S, Hameed M (1994) Abnormal insulin and glucose metabolism in the JCR:LA-corpulent rat. Metabolism 43:538–543
Velasquez MT, Kimmel PL, Michaelis OE,IV (1990) Animal models of spontaneous diabetic kidney disease. FASEB J 4:2850–2859
Yen T, Shaw WN, Yu PL (1977) Genetics of obesity in Zucker rats and Koletsky rats. Heredity 38:373–377
Dophin PJ, Stewart B, Amy RM, Russell JC (1987) Serum lipids and lipoproteins in the atherosclerotic-prone LA/N-corpulent rat. Biochem Biophys Acta 919:140–148
Pederson RA, Campos RV, Buchan AMJ, Chisholm CB, Russell JC, Brown JC (1991) Comparison of the enteroinsular axis in two strains of obese rat, the fatty Zucker and the JCR:LA-corpulent. Int J Obesity 15:461–470
Russell JC, Amy RM (1986a) Early arteriosclerotic lesions in a susceptible rat model: the LA/N-corpulent rat. Arteriosclerosis 60:119–129
Russell JC, Amy RM (1986b) Myocardial and vascular lesions in the LA/N-corpulent rat. Can J Physiol Pharmacol 64:1272–1280
Russell JC, Graham S, Hameed M (1994) Abnormal insulin and glucose metabolism in the JCR:LA-corpulent rat. Metabolism 43:538–543
Vydelingum S, Shillabeer G, Hatch G, Russell JC, Lau DCW (1995) Overexpression of the obese gene in the genetically obese JCR:LA-corpulent rat. Biochem Biophys Res Commun 216:148–153
Clark RG, Mortensen DL, Carlsson LMS, Carlsson B, Carmignac D, Robinson ICAF (1996) The obese growth hormone (GH)-deficient dwarf rat: Body fat responses to patterned delivery of GH and insulin-like growth factor-I. Endocrinology 137:1904–1912
References
Bartke A, Gorecki A (1968) Oxygen consumption by obese yellow mice and their normal littermates. Am J Physiol 214:1250–1252
Bateson W (1903) The present state of knowledge of colors heredity in mice and rats. Proc Zool Soc London 2:71–99
Carpenter KJ, Mayer J (1958) Physiological observations on yellow obesity in the mouse. Am J Physiol 193:499–504
Cuenot L (1905) Les races pures et leur combinaisons chez les souris. Arch Zool Exp Gen 122:123–132
Dickerson GE, Gowan JW (1967) Hereditary obesity and efficient food utilization in mice. Science 105:496–498
Dickie MM, Wooley GW (1946) the age factor in weight of yellow and “thin-yellows” revealed in litter-mate comparisons. J Hered 37:365–358
Eaton GJ, Green MM (1962) Implantation and lethality of the yellow mouse. Genetica 33:106–112
Fenton PF, Chase HB (1951) Effect of diet on obesity of yellow mice in inbred lines. Proc Soc Exp Biol Med 77:420–422
Gill AM, Yen TT (1991) Effects of ciglitazone on endogenous plasma islet amyloid polypeptide and insulin sensitivity in obese-diabetic viable yellow mice. Life Sci 48:703–710
Hollifield G, Parson W (1957) Food drive and satiety in yellow mice. Am J Physiol 189:36–38
Lataste F (1883) Trois questions: naturaliste. Bull Sci du Dep du Nord 8:364
Pedersen RA (1974) Development of lethal yellow (Ay/Ay) mouse embryos in vitro. J Exp Zool 188:307–320
Robertson GG (1942) An analysis of the development of homozygous yellow mouse embryos. J Exp Zool 89:197–230
Silberberg R, Silberberg M (1957) Lesions in “yellow” mice fed stock, high-fat or high-carbohydrate diets. Yale J Biol Med 29:525–539
Diani AR, Sawada GA, Zhang NY, Wyse BM, Connell CL, Vidmar TJ, Connell MA (1987) The KKAy mouse: a model for the rapid development of glomerular capillary basement membrane thickening. Blood Vessels 24:297–303
Hofmann CA, Edwards CW, Hillman RM, Colca JR (1992) Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression. Endocrinol 130:735–740
Iwatsuka H, Shino A, Suzouki Z (1970) General survey of diabetic features of yellow KK mice. Endocrinol Japon 17:23–35
Shafrir E (1992) Animal models of non-insulin-dependent diabetes. Diabetes/Metab Rev 8:179–208
Sohda T, Momose Y, Meguro K, Kawamatsu Y, Sugiyama Y, Ikeda H (1990) Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneim Forsch/Drug Res 40:37–42
Yoshida T, Hiraoka N, Yoshioka K, Hasegawa G, Kondo M (1991) Anti-obesity and anti-diabetic actions of a, BRL 28630A, in yellow kk mice. Endocrinol Japon 38:397–403
Yoshida T, Umekawa T, Wakabayashi Y, Yoshimoto K, Sakane N, Kondo M (1996) Anti-obesity and anti-diabetic effects of mazindol in yellow kk mice: its activating effect on brown adipose tissue thermogenesis. Clin Exp Pharmacol Physiol 23:476–482
Bleisch VR, Mayer J, Dickie MM (1952) Familial diabetes mellitus in mice associated with insulin resistance, obesity and hyperplasia of the islands of Langerhans. Am J Pathol 28:369–385
Boissenault GA, Hornshuh MJ, Simons JW, Romsos DR, Leveille GA (1976) Oxygen consumption of lean and obese (ob/ob) mice from birth to 16 weeks of age. Fed Proc 36:1150
Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P (1995) Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 269:546–549
Chehab FF, Lim ME, Lu R (1996) Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nature Genet 12:318–322
Chlouverakis C (1972) Insulin resistance of parabiotic obese-hyperglycemic mice (obob). Horm Metab Res 4:143–148
Chlouverakis C, White PA (1969) Obesity and insulin resistance in the obese-hyperglycemic mouse (obob). Metabolism 18:998–1006
Coleman DL (1973) Effects of parabiosis of obese with diabetes and normal mice. Diabetologia 9:294–298
Coleman DL (1989) Therapeutic effects of dehydroepiandrosterone and its metabolites in diabetes-obesity mutants. In: Lardy H, Stratman F (eds) Hormones, Thermogenesis and Obesity. Elsevier, New York, pp 377–383
Coleman DL, Hummel KP (1973) The influence of genetic background on the expression of obese (ob) gene in the mouse. Diabetologia 9:287–293
Cresto JC, Lavine RL, Buchly ML, Penhos JC, Bhathena SJ, Recant L (1977) Half life of injected 125I-insulin in control and ob/ob mice. Acta Physiol Lat Am 27:7–15
Dickie MM (1962) New mutations. Mouse News Letter 27:37
Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM (1955) Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269:543–546
Hellman B (1967) Some metabolic aspects of the obese-hyperglycemic syndrome in mice. Diabetologia 3:222–229
Herberg L, Coleman DL (1977) Laboratory animals exhibiting obesity and diabetes syndromes. Metabolism 26:59–99
Ingalls AM, Dickie MM, Snell GT (1950) Obese, a new mutation in the house mouse. J Hered 14:317–318
Mayer J, Bates MW, Dickie MM (1951) Hereditary diabetes in genetically obese mice. Science 113:746–747
Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F (1995) Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269:540–543
Roupas P, Towns RJ, Kostyo JL (1990) Isolated adipocytes from growth hormone-treated obese (ob/ob) mice exhibit insulin resistance. Biochim Biophys Acta 1052:341–344
Sirek A (1968) Spontaneous hereditary diabetes in laboratory animals. in: Pfeiffer EF (ed) Handbook of Diabetes mellitus, Pathophysiology and Clinical Considerations. Vol. I, Lehmanns Verlag, München. pp 715–726
Stauffacher W, Lambert AE; Vecchio D, Renold AE (1967) Measurement of insulin activities in pancreas and serum of mice with spontaneous (“obese” and “New Zealand obese”) and induced (goldthioglucose) obesity and hyperglycemia, with considerations on the pathogenesis of the spontaneous syndrome. Diabetologia 3:230–237
Stein JM, Bewsher PD, Stowers JN (1970) The metabolism of ketones, triglyceride and monoglyceride in livers of obese hyperglycaemic mice. Diabetologia 6:570–574
Strautz RL (1970) Studies of hereditary-obese mice (obob) after implantation of pancreatic islets in Millipore filter capsules. Diabetologia 6:306–312
Trayhurn P, Thurlby PL, James WPT (1977) Thermogenic defect in pre-obese ob/ob mice. Nature 266:60–62
Trayhurn P, Thomas MEA, Duncan JS, Rayner DV (1996) Effects of fasting and refeeding on ob gene expression in white adipose tissue of lean and obese (ob/ob) mice. FEBS Lett 368:488–490
Westman S (1968) Development of the obese-hyperglycaemic syndrome in mice. Diabetologia 4:141–149
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372:425–432
Coleman DL, Hummel KP (1973) The influence of genetic background on the expression of the obese (ob) gene in the mouse. Diabetologia 9:287–293
Genuth SM, Przybyslski RS, Rosenberg DM (1971) Insulin resistance in genetically obese hyperglycemic mice. Endocrinology 88:1230–1238
Ingalls AM, Dickie MM, Snell GD (1950) Obese, a new mutation in the mouse. J Hered 41:317–318
Joosten HFP, van der Kroon PHW (1974) Enlargement of epididymal adipocytes in relation to hyperinsulinemia in obese mice (obob). Metabolism 23:59–66
Bielschowsky M, Bielschowsky F (1953) A new strain of mice with hereditary obesity. Proc Univ Otago Med School 31:29–31
Cofford OB, Davis CK (1965) Growth characteristics, glucose tolerance and insulin sensitivity of New Zealand obese mice. Metabolism 14:271–280
Herberg L, Major E, Hennings U, Grüneklee G, Freytag G, Gries FA (1970) Differences in the development of the obese-hyperglycemic syndrome in obob and NZO mice. Diabetologia 6:292–299
Melez KA; Harrison LC, Gilliam JN, Steinberg AD (1980) Diabetes is associated with autoimmunity in the New Zealand obese (NZO) mouse. Diabetes 29:835–840
Seemayer TA, Colle E (1980) Pancreatic cellular infiltrates in autoimmune-prone New Zealand black mice. Diabetologia 19:216–221
Shafrir E (1992) Animal models of non-insulin-dependent diabetes. Diabetes/Metab Rev 8:179–208
Velasquez MT, Kimmel PL, Michaelis OE (1990) Animal models of spontaneous diabetic kidney disease. FASEB J 4:2850–2859
Veroni MC, Proietto J, Larkins RG (1991) Insulin resistance in New Zealand obese mice. Diabetes 40:1480
Campbell IL, Das AK (1982) A spontaneous diabetic syndrome in the CBA/Ca laboratory mouse. Biochem Soc Trans 10:392
Connelly DM, Taberner PV (1985) Insulin independent diabetes in male mice from an inbred CBA strain. Endocrinol 104(Suppl):139
Connelly DM, Taberner PV (1989) Characterization of spontaneous diabetes obesity syndrome in mature CBA/Ca mice. Pharmacol Biochem Behav 34:255–259
Sclafani A (1984) Animal models in obesity: classification and characterization. Int J Obes 8:491–508
Coleman DL, Eicher EM (1990) Fat (fat) and tubby (tub): two autosomal recessive mutations causing obesity syndromes in the mouse. J Hered 88:424–427
Cool DR, Normant E, Shen F, Chen H, Pannell L, Zhang Y, Loh YP (1997) Carboxypeptidase E is a regulated secretory pathway sorting receptor: genetic obliteration leads to endocrine disorders in Cpe/fat mice. Cell 88:73–83
Naggert JK, Fricker DL, Varlamov O, Nishina PM, Rouille Y, Steiner DF, Carroll RJ, Paigen BJ, Leiter EH (1995) Hyperproinsulinaemia in obese fat/fat mice associated with a carboxypeptidase E mutation which reduces enzyme activity. Nat Genet 10:135–142
Naggert J, Harris T, North M (1997) The genetics of obesity. Curr Opin Genet Devel 7:398–404
Rovere C, Viale A, Nahon J, Kitabgi P (1996) Impaired processing of brain proneurotensin and promelanin-concentrating hormone in obese fat/fat mice. Endocrinology 137:2954–2958
Coleman DL, Eicher EM (1990) Fat (fat) and tubby (tub): two autosomal recessive mutations causing obesity syndromes in the mouse. J Hered 88:424–427
Heckenlively JR, Chang B, Erway LC, Peng C, Hawes NL, Hageman GS, Roderick TH (1995) Mouse model for Usher syndrome: linkage mapping suggests homology to Usher type I reported at human chromosome 11p15. Proc Natl Acad Sci USA 92:11100–11104
Kleyn PW, Fan W, Kovats SG, Lee JJ, Pulido JC, Wu Y, Berkemeier LR, Misumi DJ, Holmgren L, Charlat O (1996) Identification and characterization of the mouse gene tubby: a member of a novel gene family. Cell 85:281–290
Noben-Trauth K, Naggert JK, North MA, Nishina PM (1996) A candidate gene for the mouse mutation tubby. Nature 380:534–538
References
Bray G, Bouchard C (1997) Genetics and human obesity: research directions. FASEB J 11:937–945
Jensen DR, Schlaepfer IR, Morin CL, Pennington DS, Marcell T, Ammon SM, Gutierrez-Hartmann A, Eckel RH (1997) Prevention of diet-induced obesity in transgenic mice overexpressing skeletal muscle lipoprotein lipase. Am J Physiol (Regul Integr Comp Physiol) 273:R683–R689
Lowell BB, Susulic VS, Haman A, Lawitts JA, Himms-Hagen J, Boyer BB, Kozak LP, Flier JS (1993) Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature 366:740–742
References
Abadie JM, Wright B, Correa G, Browne ES, Porter JR, Svec F (1993) Effect of dihydro-epiandrosterone on neurotransmitter levels and appetite regulation of the obese Zucker rat. Diabetes 42:662–669
Anelli M, Bizzi A, Caccia S, Codegoni AM, Fracasso C, Garattini S (1992) Anorectic activity of fluoxetine and norfluoxetine in mice, rats, and guinea pigs. J Pharm Pharmacol 44:696–698
Antelman SM, Szechtman H (1975) Tail pinch induces eating in sated rats which appears to depend on nigrostriatal dopamine. Science 189:731–733
Bowden CR, Karkanias CD, Bean AJ (1988) Re-evaluation of histidyl-proline diketopiperazine [cyclo(his-pro)] effects on food intake in the rat. Pharmacol Biochem Behav 29:357–363
Caccia S, Anelli M, Fracasso C, Frittoli E, Giorcelli P, Gobbi M, Taddei C, Garattini S, Mennini T (1993) Anorectic effect and brain concentrations of D-fenfluramine in the marmoset: relationship to the in vivo and in vitro effects on serotonergic mechanisms. Naunyn Schmiedeberg's Arch Pharmacol 347:306–312
Clark JM, Clark AJM, Winn P (1992) N-methyl-D-aspartate lesions of the lateral hypothalamus do not reduce amphetamine or fenfluramine anorexia but enhance the acquisition of eating in response to tail pinch in the rat. Psychopharmacology 109:331–337
Cooper SJ, Dourish CT, Barber DJ (1990a) Fluoxetine reduces food intake by a cholecystokinin-independent mechanism. Pharmacol Biochem Behav 35:51–54
Cooper SJ, Dourish CT, Barber DJ (1990b) Reversal of the anorectic effect of (+)-fenfluramine in the rat by the selective cholecystokinin receptor antagonist MK-329. Br J Pharmacol 99:65–70
Cooper SJ, Francis J, Rusk IN (1990c) The anorectic effect of SK&F 38393, a selective dopamine D1 agonist: a microstructural analysis of feeding and related behavior. Psychopharmacology 100:182–187
Cooper SJ, Francis J, Barber DJ (1993) Selective dopamine D-1 receptor antagonists, SK&F 38393 and CY 208–243 reduce sucrose sham-feeding in the rat. Neuropharmacol 32:101–102
Dourish CT, Hutson PH, Curzon G (1985) Low doses of the putative serotonin agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) elicit feeding in the rat. Psychopharmacology 86:197–204
Dourish CT, Hutson PH, Curzon G (1986) Para-chlorophenyl-alanine prevents feeding induced by the serotonin agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). Psychopharmacology 89:467–471
Eberle-Wang K, Simansky KJ (1992) The CCK-A receptor antagonist, devazipide, blocks the anorectic action of CCK but not peripheral serotonin in rats. Pharmacol Biochem Behav 43:943–947
Fantino M, Cabanac M (1980) Body weight regulation with a proportional hoarding response. Physiol Behav 24:939–942
Fantino M, Faïon F, Roland Y (1986) Effect of dexfenfluramine on body weight set-point: Study in the rat with hoarding behavior. Appetite 7 (Suppl):115–126
Fantino M, Boucher H, Faïon F, Mathiot P (1988) Dexfenfluramine and body weight regulation: experimental study with hoarding behavior. Clin Neuropharmacol 11 (Suppl 1):S97–S104
Ferrari F, Pelloni F, Giuliani D (1992) B-HT 920 stimulates feeding and antagonizes anorexia induced by ACTH and immobilisation. Eur J Pharmacol 210:17–22
Fray PJ, Koob GF, Iversen SD (1982) Tail-pinch-elicited behavior in rats: preference, plasticity and learning. Behav Neural Biol 36:108–136
Garattini S (1992) An update on the pharmacology of serotoninergic appetite-suppressive drugs. Int J Obesity 16/Suppl 14:S41–S48
Garattini S, Bizzi A, Codegoni AM, Caccia S, Mennini T (1992a) Progress report on the anorexia induced by drugs believed to mimic some of the effects of serotonin on the central nervous system. Am J Clin Nutr 55:160S–166S
Garattini S, Bizzi A, Caccia S, Mennini T (1992b) Progress report on the anorectic effects of dexfenfluramine, fluoxetine and sertaline. Intern J Obesity 16/Suppl 3:S43–S50
Gilbert F, Dourish CT (1987) Effects of the novelanxiolytics gespirone, buspirone and ipsapirone on free feeding and on feeding induced by 8-OH-DPAT. Psychopharmacology 93:349–352
Hammer VA, Gietzen DW, Beverly JL, Rogers QR (1990) Serotonin3 receptor antagonists block anorectic responses to amino acid imbalance. Am J Physiol, Regul Integr Comp Physiol 259:R627–R636
Hull KM, Maher TJ (1990) L-Tyrosine potentiates the anorexia induced by mixed-acting sympathomimetic drugs in hyperphagic rats. J Pharm Exp Ther 255:403–409
Jackson HC, Bearham MC, Hutchins LJ, Mazurkiewicz SE, Needham AM, Heal DJ (1997) Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 121:1613–1618
Knoll J (1979) Satietin: A highly potent anorexogenic substance in human serum. Physiol Behav 23:497–502
Knoll J (1984) Satietin: A 50 000 dalton glycoprotein in human serum with potent, long-lasting and selective anorectic activity. J Neural Transmiss 59:163–194
Leung PMB, Rogers QR (1969) Food intake: regulation by plasma amino acid pattern. Life Sci 8:1–9
Maher TJ, Hull KM (1990) Effects of L-tyrosine on the anorectic activity of mixed-acting sympathomimetics in hyperphagic rats. Eur J Pharmacol 183:429–430
Mennini T, Bizzi A, Caccia S, Codegoni A, Fracasso C, Frittoli E, Guiso G, Padura IM, Taddei C, Uslenghi A, Garattini S (1991) Comparative studies on the anorectic activity of d-fenfluramine in mice, rats and guinea pigs. Naunyn Schmiedeberg's Arch Pharmacol 343:483–490
Nagy J (1994) Purification of the anorectic agents satietin from bovine serum. Pharmacol Biochem Behav 48:17–22
Nishida KJ, Dougherty GG, Ellinwood EH, Rockwell WJK (1990) Effects of chronic chlorimipramine and imipramine administration on food hoarding behavior in male rats. Res Commun Psychol Psychiatry Behav 15:115–128
Robert JJ, Orosco M, Rouch C, Jacquot C, Cohen Y (1989) Unexpected responses of the obese “cafeteria” rat to the peptide FMRF-amide. Pharmacol Biochem Behav 34:341–344
Rosofsky M, Geary N (1989) Phenylpropanolamine and amphetamine disrupt postprandial satiety in rats. Pharmacol Biochem Behav 34:797–803
Rouru J, Huuponen R, Pesonen U, Koulu M (1992) Subchronic treatment with metformin produces anorectic effect and reduces hyperinsulinemia in genetically obese Zucker rats. Life Sci 50:1813–1820
Samanin R, Mennini T, Ferraris A, Bendotti C, Borsini F, Garattini S (1979) m-Chlorophenylpiperazine: A central serotonin agonist causing powerful anorexia in rats. Naunyn-Schmiedeberg's Arch Pharmacol 308:159–163
Simansky KJ, Vaidya AH (1990) Behavioral mechanisms for the anorectic action of the serotonin (5-HT) uptake inhibitor sertaline in rats: comparison with directly acting 5-HT agonists. Brain Res Bull 25:953–960
Simmons RD, Blosser JC, Rosamond JR (1994) FPL 14294: A novel CCK-8 agonist with potent intranasal anorectic activity in the rat. Pharmacol Biochem Behav 47:701–708
Stevens R, Edwards S (1996) Effect of a 5-HT3 antagonist on peripheral 5-hydroxytryptamine-induced anorexia. Psychobiology 24:67–70
Thurlby PL, Samanin R (1981) Effects of anorectic drugs and prior feeding on food-rewarded runway behavior. Pharmacol Biochem Behav 14:799–804
Vergoni AV, Poggioli R, Marrama D, Bertolini A (1990) Inhibition of feeding by ACTH-(1–24): behavioral and pharmacological aspects. Eur J Pharmacol 179:347–355
Voigt JP, Fink H, Marsden CA (1995) Evidence for the involvement of the 5-HT1A receptor in CCK induced satiety in rats. Naunyn-Schmiedeberg's Arch Pharmacol 351:217–220
References
Arch JRS, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, Thody VE, Wilson C, Wilson S (1984) Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 309:163–165
Foster DO (1986) Quantitative role of brown adipose tissue in thermogenesis. In: Trayhurn P, Nicholls DG (eds) Brown Adipose Tissue. Edward Arnold, Ltd., London, pp 31–51
Halloway BR (1989) Selective β-agonists of brown fat and thermogenesis. In: Lardy H, Stratman F (eds) Hormones, Thermogenesis and Obesity. Elsevier, New York, pp 477–484
Himms-Hagen J (1989) Brown adipose tissue thermogenesis and obesity. Progr Lipid Res 28:67–115
Isler D, Hill HP, Meier MK (1987) Glucose metabolism in isolated brown adipocytes under β-adrenergic stimulation. Quantitative contribution of glucose to total thermogenesis. Biochem J 245:789–793
Kajita J, Kobayashi S, Yoshida T (1994) Effect of benidipine hydrochloride on regional blood flow of the adipose tissue in anesthetized rats. Arzneim Forsch/Drug Res 44:297–300
Milner RE, Wilson S, Arch JRS, Trayhurn A (1988) Acute effects of a β-adrenoceptor agonist (BRL 26830A) on rat brown adipose tissue mitochondria. Biochem J 249:759–763
Nedergaaard J, Jacobsson A, Cannon B (1989) Adrenergic regulation of thermogenin activity and amount in brown adipose tissue. In: Lardy H, Stratman F (eds) Hormones, Thermogenesis and Obesity. Elsevier, New York, pp 105–116
Nicholls DG (1976) Hamster-brown-adipose tissue mitochondria: purine nucleotide control of the ionic conductance of the inner membrane, the nature of the nucleotide binding site. Eur J Biochem 62:223–228
Nicholls DG, Cunningham SA, Rial E (1986) The bioenergetic mechanisms of brown adipose tissue thermogenesis. In: Trayhurn P, Nicholls DG (eds) Brown Adipose Tissue. Edward Arnold, Ltd., London, pp 52–85
Peterson GL (1977) A simplification of the protein assay method of Lowry et al. which is generally more applicable. Anal Biochem 83:346–356
Ricquier D, Mory G (1984) Factors affecting brown adipose tissue in animals and man. Clinics Endocrinol Metab 13:501–521
Ricquier D, Bouillaud F (1986) The brown adipose tissue mitochondrial uncoupling protein. In: Trayhurn P, Nicholls DG (eds) Brown Adipose Tissue. Edward Arnold, Ltd., London, pp 86–104
Santti E, Huupponen R, Rouro J, Hänninen V, Pesonen U, Jhanwar-Uniyal M, Koulu M (1994) Potentiation of the anti-obesity effect of the β3-adrenoceptor agonist BRL 35135 in obese Zucker rats by exercise. Br J Pharmacol 113:1231–1236
Savontaus E, Raasmaja A, Rouru J, Koulu M, Pesonen U, Virtanen R, Savola JM, Huupponen R (1997) Anti-obesity effect of MPV-1743 A III, a novel imidazoline derivative, in genetic obesity. Eur J Pharmacol 328:207–215
Swick RW, Henningfield MF (1989) Changes in the number of GDP binding sites on brown adipose tissue (BAT) mitochondria and its uncoupling protein. In: Lardy H, Stratman F (eds) Hormones, Thermogenesis and Obesity. Elsevier, New York, pp 117–127
Takahashi H, Nakano K, Yasuda TT, Komiyma Y, Muakami T, Nishimura M, Nakanishi T, Sakamoto SH, Nanbu A, Yoshimura M (1994) Anti-obesity and anti-diabetic effects of carterenol in non-insulin dependent diabetic mice. Clin Exp Pharmacol Physiol 21:477–483
Yoshida T, Nishioka H, Nakamura Y, Kondo M (1984) Reduced norepinephrine turnover in mice with monosodium glutamateinduced obesity. Metabolism 33:1060–1063
Yoshida T, Nishioka H, Nakamura Y, Kanatsuna T, Kondo M (1985) Reduced norepinephrine turnover in brown adipose tissue of pre-obese mice treated with monosodium-L-glutamate. Life Sci 36:931–938
Yoshida T, Hiraoka N, Yoshioka K, Hasegawa G, Kondo M (1991) Anti-obesity and anti-diabetic actions of a β3-adrenoceptor agonist, BRL 28630A, in yellow kk mice. Endocrinol Japon 38:397–403
Yoshida T, Sakane N, Wakabayashi Y, Umekawa T, Kondo M (1994a) Anti-obesity and anti-diabetic effects of CL 316,243, a highly specific β3-adrenoceptor agonist, in yellow KK mice. Life Sci 54:491–498
Yoshida T, Umekawa T, Wakabayashi Y, Sakane N, Kondo M (1994b) Mechanism of anti-obesity action of bendipine hydrochloride in mice. Int J Obesity 18:776–779
Yoshida T, Umekawa T, Wakabayashi Y, Yoshimoto K, Sakane N, Kondo M (1996) Anti-obesity and anti-diabetic effects of mazindol in yellow kk mice: its activating effect on brown adipose tissue thermogenesis. Clin Exp Pharmacol Physiol 23:476–482
Umekawa T, Yoshida T, Sakane N, Saito M, Kumamoto K (1997) Anti-obesity and anti-diabetic effects of CL316,243, a highly specific β3-adrenoceptor agonist, in Otsuka Long Evans Tokushima Fatty rats: induction of uncoupling protein and activation of glucose transporter 4 in white fat. Eur J Endocrinol 136:429–437
References
Bartness TJ, Billington CJ, Levine AS, Morley JE, Brown DM, Rowland ME (1986) Insulin and metabolic efficacy in rats. I. Effects of sucrose feeding and BAT axotomy. Am J Physiol 251:R1108–R1117
Berraondo B, Matrti A, Duncan JS, Trayhurn P, Martinez JA (2000) Up-regulation of muscle UPC2 gene expression by a new β3-adrenoceptor agonist, trecadrine, in obese (cafeteria) rodents, but down-regulation in lean animals. Int J Obes 24:156–163
Boss O, Samec S, Paolini-Giacobino A, Rossier C, Dulloo A, Seydoux J, Muzzin P, Giacobino JP (1997) Uncoupling protein-3: A new member of the mitochondrial carrier family with tissue-specific expression. FEBS Lett 408:39–42
Branco M, Ribeiro M, Negrao N, Bianco C (1999) 3,5,3′-Triiodothyronine actively stimulates UCP in brown fat under minimal sympathetic activity. Am J Physiol 276; Endocrinol Metab 39:E179–E187
Fleury C, Neverova M, Collins S, Raimbault S, Champigny O, Levi-Meyrueis C, Bouillaud F, Seldin MF, Surwit RS, Ricquier D, Warden CH (1997) Uncoupling protein-2: A novel gene linked to obesity and hyperinsulinemia. Nat Genet 15:269–272
Foellmi-Adams LA, Wyss BM, Herron D, Nedergaard J, Kletzien RF (1996) Induction of uncoupling protein in brown adipose tissue. Synergy between norepinephrine and pioglitazone, an insulin-sensitizing agent. Biochem Pharmacol 52:693–701
Ghorbani M, Himms-Hagen J (1997) Appearance of brown adipocytes in white adipose tissue during CL316,243-induced reversal of obesity and diabetes in Zucker fa/fa rats. Int J Obes 21:465–475
Gong DW, He Y, Karas M, Reitman M (1997) Uncoupling protein-3 is a mediator of thermogenesis regulated by thyroid hormone, β3-adrenergic agonists, and leptin. J Biol Chem 272:24129–24132
Kotz CM, Wang CF, Briggs JE, Levine AS, Billington CJ (2000) Effect of NPY in the hypothalamic paraventricular nucleus on uncoupling protein 1, 2, and 3 in the rat. Am J Physiol 278, Regul Integr Comp Physiol 47:R494–R498
Lanni A, Beneduce L, Lombardi A, Moreno M, Boss O, Muzzin P, Giacobino JP, Goglia F (1999) Expression of uncoupling protein-3 and mitochondrial activity in the transition from hypothyroid to hyperthyroid state in rat skeletal muscle. FEBS Lett 444:250–254
Larkin S, Mull E, Miao W, Pittner R, Albrandt K, Moore C, Young A, Denaro M, Beaumont K (1997) Regulation of the third member of the uncoupling protein family, UCP3, by cold and thyroid hormone. Biochem Biophys Res Commun 240:222–227
Lin CS, Klingenberg M (1980) Isolation of the uncoupling protein from brown adipose tissue mitochondria. FEBS Lett 133:299–303
Liu Y L, Stock MJ, (1995) Acute effects of the β3-adrenocptor agonist, BRL 35135, on tissue glucose utilization. Br J Pharmacol 114:888–894
Liu Y L, Kashani SMZ, Heal DJ, Stock MJ, (1996) Effect of sibutramine on tissue glucose utilization in the rat. Br J Pharmacol 117:324P
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
Mao W, Yu XX, Zhong A, Li W, Brush J, Sherwood SW, Adams SA, Pan G (1999) UCP, a novel, brain-specific mitochondrial protein that reduces membrane potential in mammalian cells. FEBS Lett 443:326–330
Masaki T, Yoshimatsu H, Kakuma T, Hidaka S, Kurakawa M, Sataka T (1997) Enhanced expression of uncoupling protein 2 gene in rat white adipose tissue and skeletal muscle following chronic treatment with thyroid hormone. FEBS Lett 418:323–326
Matsuda J, Hosada K, Itoh H, Son C, Doi K, Tanaka T, Fukunaga Y, Inoue G, Nishimura H, Yoshimasa Y, Yamori Y, Nakao K (1997) Cloning of rat uncoupling protein-3 and uncoupling protein-2 cDNAs: Their gene expression in rats fed a high fat diet. FEBS Lett 418:200–204
Milner RE, Wilson S, Arch JRS, Trayhurn P (1988) Acute effects of a β-adrenoceptor agonist (BRL 26830A) on rat brown-adipose-tissue mitochondria. Biochem J 249:759–763
Nagase I, Yoshida T, Kumamoto K, Umekawa T, Sakane N, Nikami H, Kawada T, Saito M (1996) Expression of uncoupling protein in skeletal muscle and white fat of obese mice treated with thermogenic β3-adrenergic agonist. J Clin Invest 97:2898–2094
Paulik MA, Lenhard M (1997) Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression off uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells. Cell Tiss Res 290:79–87
Puigserver P, Vazquez F, Bonet ML, Pico C, Palou A (1996) In vitro and in vivo induction of brown adipocyte uncoupling protein (thermogenin) by retinoic acid. Biochem J 317:827–833
Ricquier D, Raimbault S, Champigny O, Miroux B, Bouillaud F (1992) The uncoupling protein is not expressed in rat liver. FEBS Lett 303:103–106
Savontaus E, Rouro J, Boss O, Huupponen R, Koulu M (1998) Differential regulation of uncoupling proteins by chronic treatments with β3-adrenergic agonist BRL 35135 and metformin in obese fa/fa Zucker rats. Biochem Biophys Res Commun 246:899–904
Scarpace PJ, Matheney M (1996) Thermogenesis in brown adipose tissue with age: post-receptor activation by forskolin. Eur J Physiol 431:388–394
Scarpace PJ, Matheny M, Moore RL, Kumar MV (2000) Modulation of uncoupling protein 2 and uncoupling protein 3: regulation by denervation, leptin and retinoic acid treatment. J Endocrinol 164:331–337
Shimabukuro M, Zhou YT, Unger RH (1997) Induction of uncoupling protein-2 mRNA by troglitazone in the pancreatic islets of Zucker diabetic fatty rats. Biochem Biophys Res Commun 237:359–361
Shimizu Y, Nikami H, Tsukazaki K, Machado UF, Yano H, Seino Y, Saito M (1993) Increased expression of glucose transporter GLUT-4 in brown adipose tissue of fasted rats after cold exposure. Am J Physiol 264:E890–E895
Shrago E, McTigue J, Katiyar S, Woldegiorgis C (1989) Preparation of highly purified reconstituted uncoupling protein to study biochemical mechanism(s) of proton conductance. In: Lardy H, Stratman F (eds) Hormones, Thermogenesis and Obesity. Elsevier, New York, pp 129–136
Stock MJ (1997) Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obesity 21 (Suppl 1):S25–S29
Tonello C, Dioni L, Briscini L, Nisoli E, Carruba MO (1998) SR59230A blocks β3-adrenoreceptor-linked modulation of uncoupling protein-1 and leptin in rat brown adipocytes. Eur J Pharmacol 352:125–129
Umekawa T, Yoshida T, Sakane N, Saito M, Kumamoto K, Kondo M (1997) Anti-obesity and anti-diabetic effects of CL316,243, a highly specific β3-adrenoceptor agonist, in Otsuka Long-Evans Tokushima fatty rats: induction of uncoupling protein and activation of GLUT4 in white fat. Eur J Endocrinol 136:429–437
Viadal-Puig A., Solanes G, Grujic D, Flier JS, Lowell BB (1997) UCP3: An uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. Biochem Biophys Res Commun 235:79–82
Yonetani T, Ray GS (1965) A study on cytochrome oxidase: kinetics of the aerobic oxidation of ferrocytochrome c by cytochrome oxidase. J Biol Chem 240:3392–3398
References
Ghorbani M, Claus TH, Himms-Hagen J (1997) Hypertrophy of brown adipocytes in brown and white adipose tissue and reversal of diet-induced obesity in rats treated with a β3-adrenoceptor agonist. Biochem Pharmacol 54:121–131
Himms-Hagen J, Cui J, Danforth E Jr., Taatjes DJ, Lang SS, Waters BL, Claus TH (1994) Effect of CL-316,243, a thermogenic β3-agonist, on energy balance and brown and white adipose tissue in rats. Am J Physiol 266 (Regul Integr Comp Physiol 35):R1371–1382
Jensen DR, Gayles EC, Ammon S, Phillips R, Eckel RH (2001) A self-correcting indirect calorimeter system for the measurement of energy balance in small animals. J Appl Physiol 90:912–918
Molnar JA, Cunningham JJ, Miyatani S, Vizulis A, Write JD, Burke JF (1986) Closed-circuit metabolic system with multiple applications. J Appl Physiol 61:1582–1585
Niemegeers CJE, Janssen PAJ (1979) Differential antagonism to amphetamine-induced oxygen consumption and agitation by psychoactive drugs. In: Fielding S, Lal H (eds) Industrial Pharmacology, Vol II, Antidepressants., pp 125–141
Paulik MA, Buckholz RG, Lancaster ME, Dallas WS, Hull-Ryde EA, Weiel JE, Lenhard JM (1998) Thermogenic effects of uncoupling protein-2, troglitazone, and β-adrenoceptor agonists. Pharm Res 15:944–949
Poon TKY, Cameron DP (1978) Measurement of oxygen consumption and locomotor activity in monosodium glutamateinduced obesity. Am J Physiol 234:E532–E534
Rothwell NJ (1989) Central activation of thermogesesis by prostaglandins: dependence on CRF. Horm Metab Res 22:616–618
Stock MJ (1975) An automatic close-circuit oxygen consumption apparatus for small animals. J Appl Physiol 253:1271–1276
Yoshida T, Yoshioka K, Kamanaru K, Hiraoka N, Kondo M (1990) Mitigation of obesity by BRL 26830A, a new β-adrenoceptor agonist, in MSG obese mice. J Nutr Sci Vitaminol 36:75–80
Yoshida T, Hiraoka N, Yoshioka K, Hasegawa G, Kondo M (1991) Anti-obesity and anti-diabetic actions of a β3-adrenoceptor agonist, BRL 28630A, in yellow kk mice. Endocrinol Japon 38:397–403
References
Arch JRS, Wilson S (1996) Prospects for β3-adrenoceptor agonists in the treatment of obesity and diabetes. Int J Obes 20:191–199
Carruba M, Tomello C, Briscini L, Nisoli E, Astrup A (1998) Advances in pharmacotherapy for obesity. Int J Obes 22; Suppl 1:S13–S17
Emorine L, Blin N, Strosberg AD (1994) The human β3-adrenoceptor: the search for a physiological function. Trends Pharmacol Sci 15:3–7
Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, Strosberg AD (1989) Molecular characterization of the human β3-adrenergic receptor. Science 245:1118–1121
Evans BA, Papaioannou M, Bonazzi VR, Summers RJ (1996) Expression of β3-adrenoreceptor mRNA in tissues. Br J Pharmacol 117:210–216
Evans BA, Papaioannou M, Anastasopoulos F, Summers RJ (1998) Differential regulation of β3-adrenoceptors in gut and adipose tissue of genetically obese (ob/ob) C57BL/6J mice. Br J Pharmacol 124:763–771
Galitzky J, Langin D, Montastruc JL, Lafontan M, Berlan M (1998) On the presence of a fourth β-adrenoceptor in human adipose tissue. Trends Pharmacol Sci 19:164–165
Gettys TW, Harkness PJ, Watson PM (1996) The β3-adrenergic receptor inhibits insulin-stimulated leptin secretion from isolated rat adipocytes. Endocrinology 137:4054–4057
Granneman JG, Lahners KN, Chaudry A (1991) Molecular cloning and expression of the rat β3-adrenergic receptor. Mol Pharmacol 40:895–899
He Y, Nikulin VI, Vansal SS, Feller DR, Miller DD (2000) Synthesis and human β3-adrenoceptor activity of 1-(3,5-diiodo-4-methoxybenzyl)-1,2,3,4-tetrahydroisoquinolin-6-ol derivatives in vitro. J Med Chem 43:591–598
Kaumann AJ, Preitner F, Sarsero D, Molenaar P, Revelli JP, Giacobino JP (1998) (−)-CGP 12177 causes cardiostimulation and binds to cardiac putative β4-adrenoceptors in both wild-type and β3-adrenoceptor knockout mice. Mol Pharmacol 53:670–675
Koike K, Ichino T, Horinouchi T, Takayanagi I (1997) The β2-and β3-adrenoceptor-mediated relaxation induced by isoprenaline and salbutamol in guinea pig taenia caecum. J Smooth Muscle Res 33:99–106
Kumar MV, Moore RL, Scarpace PJ (1999) β3-adrenergic regulation of leptin, food intake, and adiposity is impaired with age. Pflügers Arch Eur J Physiol 438:681–688
Nahmias C, Blin N, Elalouf JM, Mattei MG, Stroberg AD, Emorine LJ (1991) Molecular characterization of the mouse β3-adrenergic receptor: relationship with the atypical receptor of adipocytes. EMBO J 10:3721–3727
Sarsero D, Molenaar P, Kaumann AJ (1998) Validity of (−)-[3H]-CGP 12177A as a radioligand for the ‘putative β4-adrenoceptor’ in rat atrium. Br J Pharmacol 123:371–380
Strosberg AD (1997) Structure and function of the β3-adrenergic receptor. Annu Rev Pharmacol Toxicol 37:421–450
Strosberg AD, Gerhardt CC, Gros J, Jockers R, Rouxel FP (1998) On the putative existence of a fourth β-adrenoceptor: proof is still missing. Trends Pharmacol Sci 19:165–166
Tomiyama Y, Hayakawa K, Shinagawa K, Akahane M, Ajisawa Y, Park YC, Kurita T (1998) β3-adrenoceptor subtypes in the ureteral smooth muscle of rats, rabbits and dogs. Eur J Pharmacol 352:269–278
Vansal SS, Fellner DR (1999) An efficient cyclic AMP assay for the functional elevation of β-adrenergic receptor ligands. J Receptor Signal Transduct Res 19:853–863
Weyer C, Gautier JF, Danforth E Jr. (1999) Development of β3-adrenoceptor agonists for the treatment of obesity and diabetes — An update. Diabetes Metab 25:11–21
Yoshida T, Sakane N, Wakabajashi Y, Umekawa T, Kondo M (1994) Anti-obesity and anti-diabetic effects of CL 316,243, a highly specific beta3-adrenoceptor agonist, in yellow KK mice. Life Sci 54:491–498
References
Ahima RS, Flier JS (2000) Adipose tissue as an endocrine organ. Trends Endocrin Metab 11:327–332
Bacher D, Kreienkamp HJ, Weise C, Buck F, Richter D (1999) Identification of melanin concentrating hormone (MHC) as the natural ligand for the orphan somatostatin-like receptor 1 (SLC-1) FEBS Lett 467:522–524
Berger A (2001) Resistin, a new hormone that links obesity with type 2 diabetes. Br Med J 322:193
Broberger C (1999) Hypothalamic cocaine-and amphetamine-regulated transcript (CART) neurons. Histochemical relationship to thyrotropin-releasing hormone, melatonin-concentrating hormone, orexin/hypocretin and neuropeptide Y. Brain Res 848:101–113
Broberger C, Holmberg K, Kuhar MJ, Hökfelt T (1999) Cocaine-and amphetamine-regulated transcript in the rat vagus nerve: A putative mediator of cholecystokinin-induced satiety. Proc Natl Acad Sci USA 96:13506–13511
Burgaud JL, Poosti R, Fehrentz JA, Martinez J, Nahon JL (1997) Melanin-concentrating hormone binding sites in human SVK14 keratinocytes. Biochem Biophys Res Commun 241:622–629
Chambers J, Ames RS, Bergsma D, Muir A, Fitzgerald LR, Hervieu G, Dytko GM, Foley JJ, Martin S, Liu WS, Park J, Ellis C, Ganguly S, Konchar S, Cluderay J, Leslie R, Wilson S, Sarau HM (1999) Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. Nature 400:261–265
Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee JL, Bauer TL, Caro JF (1996) Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292–295
Couceyro PR, Lambert PD (1999) CART peptides: Therapeutic potential in obesity and feeding disorders. Drug News Perspect 12:133–136
Crawley JN, Austin MC, Fiske SM, Martin B, Consolo S, Berthold M, Langel U, Fisone G, Bartfai T (1990) Activity of centrally administered galanin fragments on stimulation of feeding behavior and on galanin receptor binding in the rat hypothalamus. J Neurosci 10:3695–3700
Dun NJ, Dun SL, Kwok EH, Yang J, Chang J-K (2000) Cocaine-and amphetamine-regulated transcript-immunoreactivity in the rat sympatho-adrenal axis. Neurosci Lett 283:97–100
Elmquist JK, Elias CF, Saper CB (1999) From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 22:221–232
Fong TM, Mao C, MacNeil T, Kalyani R, Smith T, Weinberg T, Tota MR, Van der Ploeg LH (1997) ART (protein product of agouti-related transcript) as an antagonist of MC-3 and MC-4 receptors. Biochem Biophys Res Commun 237:629–631
Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395:763–770
Hintermann E, Drozdz R, Tanner H, Eberle AN (1999) Synthesis and characterization of new radioligands for the mammalian melanin-concentrating hormone (MCH) receptor. J Recept Signal Transduction Res 19:411–422
Huang Q, Viale A, Picard F, Nahon JL, Richard D (1999) Effect of leptin on melanin-concentrating hormone expression in the brain of lean and obese Lep(ob)/Lep(ob) mice. Neuroendocrinology 69:145–153
Jain MR, Horvath TL, Kalra PS, Kalra SP (2000) Evidence that NPY Y1 receptors are involved in stimulation of feeding by orexins (hypocretins) in sated rats. Regul Pept 87:19–24
Jensen PB, Kristensen P, Clausen JT, Judge ME, Hastrup S, Thim L, Wulff BS, Foged C, Jensen J, Holst JJ, Madsen OD (1999) The hypothalamic satiety peptide CART is expressed in anorectic and non-anorectic pancreatic islets tumors and in the normal islet of Langerhans. FEBS Lett 447:139–143
Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS (1999) Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 20:68–100
Kastin AJ, Akerström V (1999) Entry of CART into brain is rapid but not inhibited by excess CART or leptin. Am J Physiol 277; Endocrinol Metab 40:E901–E904
Koylu EO, Couceyro PR, Lambert PD, Kuhar MJ (1998) Cocaine-and amphetamine-regulated transcript peptide immunohistochemical localization in the rat brain. J Comp Neurol 391:115–132
Koylu EO, Smith Y, Couceyro PR, Kuhar MJ (1999) CART peptides colocalize with tyrosine hydroxylase neurones in rat locus coeruleus, Synapse 31:309–311
Kristensen P, Judge ME, Thim L, Ribel U, Christijansen KN, Wulff BS, Clausen JT, Jensen PB, Madsen OD, Vrang N, Larsen PJ, Hastrup S (1998) Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393:72–76
Kuhar MJ, Dall-Vechia SE (1999) CART peptides: Novel addiction-and feeding-related peptides. Trends Neurosci 22:316–320
Lambert PD, Wilding JPH, al Dokhayel AAM, Bohuon C, Comoy E, Gilbey SG, Bloom SR (1993) A role for neuropeptide Y, dynorphin, and noradrenaline in the central control of food intake after food deprivation. Endocrinology 133:29–33
Lambert PD, Couceyro PR, McGirr KM, Vechia SED, Smith Y, Kuhar MJ (1998) CART peptides in the central control of feeding and interaction with neuropeptide Y. Synapse 29:293–298
Leibowitz SF, Kim T (1992) Impact of a galanin antagonist on exogenous galanin and natural patterns of fat ingestion. Brain Res 599:148–152
Ludwig DS, Mountjoy KG, Tatro JB, Gillette JA, Frederich RC, Flier JS, Marato-Flier E (1998) Melanin-concentrating hormone: A functional melanocortin antagonist in the hypothalamus. Am J Physiol 274; Endocrinol Metab 37:E627–E633
Marsh DJ, Hollopeter G, Huszar D, Laufer R, Yagaloff KA, Fisher SL, Burn P, Palmiter RD (1999) Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nature Genetics 21:119–122
Ollmann MM, Wilson BD, Yang Y-K, Kerns JA, Chen Y, Gantz I, Barsh GS (1997) Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278:135–138
Ollmann MM, Lamoreux ML, Wilson BD, Barsh GS (1998) Interaction of Agouti protein with the melanocortin-1 receptor in vitro and in vivo. Genes Dev 12:316–3330
Parker EM (1999) The role of central neuropeptide, neurotransmitter and hormonal systems in the regulation of body weight. Neurotransmiss 15:3–11
Qu D, Ludwig DS, Gammeltoft S, Piper M, Pellemounter A, Cullen MJ, Foulds-Mathes W, Przypek J, Kanarek R, Maratos-Flier E (1996) A role for melatonin-concentrating hormone in the control of feeding behavior. Nature 380:243–237
Rosenfeld RD, Zeni L, Welcher AA, Narhi LO, Hale C, Marasco J, Delaney J, Gleason T, Philo JS, Katta V, Hui J, Baumgartner J, Graham M, Stark KL, Karbon W (1998) Biochemical and biophysical characterization of bacterially expressed human agouti-related protein. Biochemistry 37:16041–16052
Rossi M, Beak SA, Choi SJ, Small CJ, Morgan DGA, Ghatei MA, Smith DM, Bloom SR (1999) Investigation of the feeding effects of melanin concentrating hormone on food intake. Action independent of galanin and the melanocortin receptors. Brain Res 846:164–170
Sahu A (1998) Evidence that galanin (GAL), melanin-concentrating hormone (MHC), neurotensin (NT) proopiomelanocortin (POMC) and neuropeptide Y (NPY) are targets of leptin signaling in the hypothalamus. Endocrinology 139:795–798
Shutter JR, Graham M, Kinsey AC, Scully S, Lüthy R, Stark KL (1997) Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mice. Genes Dev 11:593–602
Saito Y, Nothacker HP, Wang Z, Lin SHS, Leslie F, Civelli O (1999) Molecular characterization of the melanin-concentrating hormone receptor. Nature 400:265–269
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JRS, Buckingham RB, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu W-S, Terrett JA, Elshourbagy NA, Berg-sma DJ, Yanagisawa M (1998) Orexins and orexin receptors: A family of hypothalamic neuropeptides an G protein-coupled receptors that regulate feeding behavior. Cell 92:573–585
Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos-Flier E (1998) Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 396:670–674
Shimomura Y, Mori M, Sugo T, Ishibashi Y, Abe M. Kurokawa T, Onda H, Nishimura O, Sumino Y, Fujino M (1999) Isolation and identification of melanin-concentrating hormone as the endogenous ligand for the SLC-1 receptor. Biochem Biophys Res Commun 261:622–626
Stanley BG, Magdalin W, Seirafi A, Nguyen MM, Leibowitz SF (1992) Evidence for neuropeptide Y mediation of eating produced by food deprivation and for a variant of the Y-1 receptor mediating this peptide's effect. Peptides 13:581–587
Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312
Thim L, Nielsen PF, Judge ME, Andersen AS, Diers I, Egel-Mitani M, Hastrup S (1998a) Purification and characterization of e new hypothalamic satiety peptide, cocaine and amphetamine regulated transcript (CART), produced in yeast. FEBS Lett 428:263–268
Thim L, Kristene P, Larsen PJ, Wulff BS (1998b) CART, a new anorectic peptide. Int J Biochem Cell Biol 30:1281–1284
Tota MR, Smith TS, Mao C, McNeil T, Mosley RT, Van der Ploeg LTH, Fong TM (1999) Molecular interaction of Agouti protein and Agouti-related protein with human melanocortin receptors. Biochemistry 38:897–904
Trayhurn P, Hoggard N, Mercer JG, Rayner DV (1999) Leptin: Fundamental aspects. Int J Obes 23, Suppl 1:22–28
Tritos NA, Maratos-Flier E (1999) Two important systems in energy homeostasis: Melanocortins and melanin-concentrating hormone. Neuropeptides 33:339–349
Xu B, Dube MG, Kalra PS, Farmeie WG, Kaibara A, Moldawer LL, Martin D, Kalra SP (1998) Anorectic effects of the cytokine, ciliary neurotropic factor, are mediated by hypothalamic neuropeptide Y: Comparison with leptin. Endocrinology 139:466–473
References
Arch JRS, Beeley LJ (1996) Leptin: The hormone that directs the regulation of energy balance. Pharmacol Commun 7:317–322
Ahima RS, Flier JS (2000) Leptin. Annu Rev Physiol 62:413–437
Barinaga M (1995) “Obese” protein that slims mice. Science 269:475–476
Chebab FF (2000) Leptin as a regulator of adipose mass and reproduction. Trends Pharmacol Sci 21:309–314
Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395:763–770
Grasso P, Leinung MC, Ingher SP, Lee DW (1997) In vivo effects of leptin-related synthetic peptides on body weight and food intake in female ob/ob mice. Endocrinology 138:1413–1418
Grasso P, White DW, Tartaglia LA, Leinung MC, Lee DW (1999) Inhibitory effects of leptin-related synthetic peptide 116–130 on food intake and body weight gain in female C57BL/6Job/ob mice may not be mediated by peptide activation of the long form of the leptin receptor. Diabetes 48:2204–2209
Guan X M, Hess JF, Yu H, Hey PJ, Van der Ploeg LHT (1997) Differential expression of mRNA for leptin receptor isoforms in the rat brain. Mol Cell Endocrinol 133:1–7
Hamann A, Matthaei S (1996) Regulation of energy balance by leptin. Exp Clin Endocrinol Diabetes 104:293–300
Igel M, Becker W, Herberg L, Joost HG (1997) Hyperleptinemia, leptin resistance, and polymorphic leptin receptor in the New Zealand obese mouse. Endocrinology 138:4234–4239
Liu C, Liu X J, Barry G, Ling N, Maki RA, De Souza EB (1997) Expression and characterization of a putative high affinity human soluble leptin receptor. Endocrinology 138:3548–3554
MacDougald OA, Hwang CS, Fan H, Lane MD (1995) Regulated expression of the obese gene product (leptin) in white adipose tissue and 3T3-L1 adipocytes. Proc Natl Acad Sci USA 92:9034–9037
Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern PA, Friedman JM (1995) Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nature Med 1:1155–1161
Maffei M, Stoffel M, Berone M, Moon B, Dammerman M, Ravussin E, Bogardus C, Ludwig DS, Flier JS, Talley M, Auerbach S, Friedman JM (1996) Absence of mutations in the human OB gene in obese/diabetic subjects. Diabetes 45:679–682
Murakami T, Yamashita T, Iida M, Kuwajima M, Shima K (1997) A short form of leptin receptor performs signal transduction. Biochem Biophys Res Commun 231:26–29
Sarmiento U, Benson B, Kaufman S, Ross L, Qi M, Scully S, DiPalma C (1997) Morphologic and molecular changes induced by recombinant human leptin in the white and brown adipose tissues of C57BL/6 mice. Lab Invest 77:243–256
Scarpace PJ, Matheny M, Pollock BH, Tumer N (1997) Leptin increases uncoupling protein expression and energy expenditure. Am J Physiol (Endocrin Metab) 273:E226–E230
Stephens TW, Caro JF (1998) To be lean or not to be lean. Is leptin the answer? Exp Clin Endocrin Diab 106:1–15
Stephens TW, Basinski M, Birstow PK, Bue-Valleskey JM, Burgett SG, Craft L, Hale J, Hoffmann J, Hsuing HM, Kriauciuneas A, Mackelar W, Rosteck PR Jr. Schoner B, Smith D, Tinsley FC, Zhang X, Heiman M (1995) The role of neuropeptide Y in the antiobesity action of the obese gene product. Na-ture 377:530–532
Strosberg D, Issad T (1999) The involvement of leptin in humans revealed by mutations in the leptin and leptin receptor genes. Trends Pharmacol Sci 20:227–230
Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J, Muir C, Sanker S, Moriarty A, Moore KJ, Smutko JS, Mays GG, Woolf EA, Monroe CA, Tepper RI (1995) Identification and expression cloning of a leptin receptor, OB-R. Cell 83:1263–1271
Trayhurn P, Hoggard N, Mercer JG, Rayner DV (1999) Leptin: Fundamental aspects. Int J Obes 23, Suppl 1:22–28
Widdowson PS, Upton R, Buckingham R, Arch J, Williams G (1997) Inhibition of food response to intracerebroventricular injection of leptin is attenuated in rats with diet-induced obesity. Diabetes 46:1782–178
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372:425–432
References
Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159
Frederich RC et al. (1995) Expression of ob mRNA and its encoded protein in rodents: Impact of nutrition and obesity. J Clin Invest 96:1658–1663
Frederich RC, Hamann A, Anderson S, Löllmann B, Lowell BB, Flier JS (1995) Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nature Med 1:1311–1314
Harris RBS, Ramsay TG, Smith SR, Bruch RC (1996) Early and late stimulation of ob mRNA expression in meal-fed and overfed rats. J Clin Invest 97:2020–2026
Karbowska J, Kochan Z, Zelewski L, Swierczynski J (1999) Tissue-specific effect of clofibrate on rat lipogenic enzyme gene expression. Eur J Pharmacol 370:329–336
Kochan Z, Karbowska J, Swierczynski J (1999) Effect of clofibrate on malic enzyme and leptin mRNA level in rat brown and white adipose tissue. Horm Metab Res 31:536–542
Li H Y, Wang L L, Yeh R S (1999) Leptin-immunoreactivity in the central nervous system in normal and diabetic rats. NeuroReport 10:437–442
Richards MP, Ashwell CM, McMurtry JP (2000) Quantitative analysis of leptin mRNA using competitive reverse transcription polymerase chain reaction and capillary electrophoresis with laser-induced fluorescence detection. Electrophoresis 21:792–798
Shintani M, Nishimura H, Yonemitsu S, Masuzaki H, Ogawa Y, Hosoda K, Inuoe G, Yoshimasa Y, Nakao K (2000) Downregulation of leptin by free fatty acids in rat adipocytes: Effects of triacsin C, palmitate, and 2-bromopalmitate. Metab Clin Exp 49:326–330
Zachwieja JJ, Hendry SL, Smith SR, Harris RBS (1997) Voluntary wheel running decreases adipose tissue mass and expression of leptin mRNA in Osborne-Mendel rats. Diabetes 46:1159–1166
References
Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern PA, Friedman JM (1995) Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nature Med 1:1155–1161
McGregor GP, Desaga JF, Ehlenz K, Fishcher A, Heese F, Hegele A, Lämmer C, Peiser C, Lang RE (1996) Radioimmunological measurement of leptin in plasma of obese and diabetic human subjects. Endocrinology 137:1501–1504
Surwit RS, Petro AE, Parekh P, Collins S (1997) Low plasma leptin in response to dietary fat in diabetes-and obesity-prone mice. Diabetes 46:1516–1520
Van Heek M, Compton DS, France CF, Tedesco RP, Fawzi AB, Graziano MP, Sybertz EJ, Strader CD, Davis HR jr. (1997) Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 99:385–390
Zachwieja JJ, Hendry SL, Smith SR, Harris RBS (1997) Voluntary wheel running decreases adipose tissue mass and expression of leptin mRNA in Osborne-Mendel rats. Diabetes 46:1159–1166
References
Billington CJ, Briggs JE, Grace M, Levine AS (1991) Effect of intracerebroventricular injection of neuropeptide Y on energy metabolism. Am J Physiol 260, Regul Integr Comp Physiol 29:R321–R327
Bischoff A, Avramidis P, Erdbrugger W, Munter K, Michel MC (1997) Receptor subtypes Y1 and Y5 are involved in the renal effects of neuropeptide Y. Br J Pharmacol 120:1335–1343
Blaze CA, Mannon PJ, Vigna SR, Kherani AR, Benjamin BA (1997) Peptide YY receptor distribution and subtype in the kidney: Effect on renal hemodynamics and function in rats. Am J Physiol 273: Renal Physiol 42:F545–F553
Britton KT, Southerland S, Van Uden E, Kirby D, Rivier J, Koob G (1997) Anxiolytic activity of NPY receptor agonists in the conflict test. Psychopharmacology 132:6–13
Broqua P, Wettstein JG, Rocher MN Gauthier-Martin B, Riviere PJM, Junien JL, Dahl SG (1996) Antinociceptive effects of neuropeptide Y and related peptides in mice. Brain Res 724:25–32
Chen C H, Stephens RL Jr., Rogers RC (1997) PYY and NPY: Control of gastric motility via action on Y1 and Y2 receptors in the dorsal vagal complex. Neurogastroenterol Motil 9:109–116
Criscione L, Rigollier P, Batzl-Hartmann C, Rueger H, Stricker-Krangrad A, Wyss P, Brunner L, Whitebread S, Yamaguchi Y, Gerald C, Heurich RO, Walker MW, Chiesi M, Schilling W, Hofbauer KG, Levens N (1998) Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J Clin Invest 102:2136–2145
Erickson JC, Hollopeter G, Palmiter RD (1996) Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science 274:1704–1707
Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl-Hartmann C, Smith KE, Vaysse P, Durkin MM; Laz TM, Linemeyer DL, Schaffhauser AO, Whitebread S, Hofbauer KG, Taber RI, Branchek TA, Weinshank RL (1996) A receptor subtype involved in neuropeptide Y-induced food intake. Nature 382:168–171
Goumain M, Voisin T, Lorinet AM, Balsubramaniam A, Laburthe M (1998) Pharmacological profile of the rat intestinal crypt peptide YY receptor vs. the recombinant Y5 receptor. Eur J Pharmacol 362:245–249
Hudspith MJ, Munglani R (1997) The therapeutic potential of neuropeptide Y in cardiovascular disease. Exper Opin Invest Drugs 6:437–445
Iyengar S, Li DL, Simmons RMA (1999) Characterization of neuropeptide Y-induced feeding in mice: Do Y1-Y6 receptor subtypes mediate feeding? J Pharmacol Exp Ther 289:1031–1040
Kanatani A, Kanno T, Ishihara A, Hata M, Sakuraba A, Tanaka T, Tsuchiya Y, Mase T, Fukuroda T, Fukami T, Ihara M (1999) The novel neuropeptide Y Y1 receptor antagonist J-104870: A potent feeding suppressant with oral bioavailability. Biochem Biophys Res Commun 266:88–91
Kask A, Rago L, Harro J (1996) Anxiogenic-like effect of the neuropeptide Y Y1 receptor antagonist BIBP3226. Eur J Pharmacol 317:R3–R4
Kask A, Rago L, Harro J (1998) Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: Studies with Y-1-selective antagonist BIBP3226. Br J Pharmacol 124:1507–1515
Kirby DA, Koerber SC, May JM, Hagaman C, Cullen MJ, Pelleymounter MA, Rivier JE (1995) Y1 and Y2 receptor selective neuropeptide Y analogues: Evidence for a Y1 receptor subclass. J Med Chem 38:4579–4586
Lambert PD, Wilding JPH, al Dokhayel AAM, Bohuon C, Comoy E, Gilbey SG, Bloom SR (1993) A role for neuropeptide Y, dynorphin, and noradrenaline in the central control of food intake after food deprivation. Endocrinology 133:29–33
Larhammar D (1996) Structural diversities for neuropeptide Y, peptide YY and pancreatic polypeptide. Regul Pept 65:165–174
Leibowitz SF (1994) Hypothalamic neuropeptide Y in regulation to energy balance. Ann NY Acad Sci 739:12–35
Lew MJ, Murphy R, Angus JA (1996) Synthesis and characterization of a selective peptide antagonist of neuropeptide Y vascu-lar postsynaptic receptors. Br J Pharmacol 117:1768–1772
Marsh DJ, Hollopeter G, Kafer KE, Palmiter RD (1998) Role of Y5 neuropeptide Y receptor in feeding and obesity. Nat Med 4:718–721
Matthews JE, Jansen M, Lyerly D, Cox R, Chen WJ, Koller KJ, Daniels AJ (1997) Pharmacological characterization and selectivity of the NPY antagonist GR231118 (1229U91) for different NPY receptors. Regul Pept 72:113–119
McCloskey MJD, Moriarty MJ, Tseng A, Shine J, Potter EK (1997) Activities of centrally truncated analogues of neuropeptide Y at Y1 and Y2 receptor subtypes in vivo. Neuropeptides 31:193–197
Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (1998) XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY,, and pancreatic polypeptide receptors. Pharmacol Rev 50:143–150
Parker EM (1999) The role of central neuropeptide, neurotransmitter and hormonal systems in the regulation of body weight. Neurotransmiss 15:3–11
Parker EM, Bajij CK, Balasubramaniam A, Burrier RE, Guzzi M, Hamud F, Mukhopadhyay G, Rudinski MS, Tao Z, Tice M, Xia L, Mullins DE, Salisbury BG (1998) GR23 1118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists. Eur J Pharmacol 349:97–105
Playford RJ, Cox HM (1996) Peptide YY and neuropeptide Y: two peptides intimately involved in electrolyte homeostasis. Trends Pharmacol Sci 17:436–438
Schaffhauser AO, Stricker-Krongrad A, Brunner L, Cumin F, Gerald C, Whitebread S, Criscione L, Hofbauer KG (1997) Inhibition of food intake by neuropeptide Y Y5 receptor antisense oligodeoxynucleotides. Diabetes 46:1792–1798
Shigeri Y, Ishikawa M, Ishihara Y, Fujimoto M (1998) A potent nonpeptide neuropeptide Y Y1 receptor antagonist, a benzodiazepine derivative. Life Sci 63:151–160
Small CJ, Morgan DGA, Meeran K, Heath MM, Gunn I, Edwards CMB, Gardiner J, Taylor GM, Hurley JD, Rossi M, Goldstone AP, O'Shea D, Smith DM, Ghatei MA, Bloom SR (1997) Peptide analogue studies of the hypothalamic neuropeptide Y receptor mediating pituitary adrenocorticotropic hormone release. Proc Natl Acad Sci USA 94:11686–11691
Souli A, Chariot J, Voisin T, Presset O, Tsocas A, Balasubramaniam A, Laburthe M, Roze C (1997) Several receptors mediate the antisecretory effects of peptide YY, neuropeptide Y and pancreatic polypeptide on VIP-induced fluid secretion in the rat jejunum in vivo. Peptides 18:551–557
Stanley BG, Magdalin W, Seirafi A, Nguyen MM, Leibowitz SF (1992) Evidence for neuropeptide Y mediation of eating produced by food deprivation and for a variant of the Y-1 receptor mediating this peptide's effect. Peptides 13:581–587
Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Rosteck PR, Schoner B, Smith D, Tinsley FC, Zhang X-Y, Heiman M (1995) The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 377:530–532
Sundler P, Boettcher G, Ekblad E, Hakanson R (1993) PP, PYY and NPY: occurrence and distribution in the periphery. In: Colmers WF, Walestedt C (eds) The Biology of Neuropeptide Y and Related Peptides. Humana Press, Inc., pp 157–196
Tadepalli AS, Harrington WW, Hashim MA, Matthews J, Leban JJ, Spaltenstein A, Daniels AJ (1996) Hemodynamic characterization of a novel neuropeptide Y receptor antagonist. J Cardiovasc Pharmacol 27:712–718
Wettstein JG, Early B, Junien JL, (1995) Central nervous system pharmacology of neuropeptide Y. Pharmacol Ther 65:397–414
Wieland HA, Engel W, Eberlein W, Rudolf K, Doods HN (1998) Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br J Pharmacol 125:549–555
Wyss P, Stricker-Krongard A, Brunner L, Miller J, Crossthwaite A, Whitebread S, Criscione L (1998) The pharmacology of neuropeptide Y (NPY) receptor-mediated feeding in rats characterizes better Y5 than Y1, but not Y2 or Y4 subtypes. Regul Pept 75–76:363–371
Zarrinmayeh H, Nunes AM, Ornstein PL, Zimmermann DM, Arnold MB, Schober DA, Gackenheimer SL, Bruns RF, Hipskind BA, Britton TC, Cantrell BE, Gehlert DL (1998) Synthesis and evaluation of a series of novel 2-[(4-chlorophenoxy)methyl]benzimidazoles as selective neuropeptide Y Y1 receptor antagonists. J Med Chem 41:2709–2719
References
Bischoff A, Michel MC (1999) Emerging functions for neuropeptide Y5 receptors. Trends Pharmacol Sci 20:104–106
Dumont Y, Jacques D, Bouchard P, Quirion R (1998) Species differences in the expression and distribution of the neuropeptide YY1, Y2, Y4, and Y5 receptors in rodents, guinea pig, and primate brains. J Comp Neurol 402:372–384
Dumont Y, Cadieux A, Doods H, Pheng LH, Abounader R, Hamel E, Jacques D, Regoli D, Quirion J (2000a) BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y2 receptor antagonist. Br J Pharmacol 129:1075–1088
Dumont Y, Cadieux A, Doods H, Fournier A, Quirion R (2000b) Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous system: BIBO3304 (Y1) and CGP71683A (Y5). Can J Physiol Pharmacol 78:116–125
Feletou M, Nicolas JP, Rodriguez M, Beauverger P, Galizzi JP, Boutin JA, Dehault J (1999) NPY receptor subtype in the rabbit isolated ileum. Br J Pharmacol 127:795–801
Gehlert DR, Gackenheimer SL, Schober DA, Beavers L, Gadski R, Burnett JP, Mayne N, Lundell I, Larhammer D (1996) The neuropeptide Y Y1 receptor selective radioligand, [125I][Leu31, Pro34]peptide YY, is also a high affinity radioligand for human pancreatic polypeptide 1 receptors. Eur J Pharmacol 318:485–490
Gicquiaux H, Tschopl M, Doods HN, Bucher B (1996) Discrimination between neuropeptide Y and peptide YY in the rat tail artery by the neuropeptide Y1-selective antagonist BIBP3226. Br J Pharmacol 119:1313–1318
Hedge SS, Bonhaus DW, Stanley W, Eglen RM, Moy TM, Loeb M, Shetty SG, Desouza A, Krstenansky J Pharmacological evaluation of 1229U91, a novel high-affinity and selective neuropeptide Y Y1 receptor. J Pharmacol Exp Ther 275:1261–1266
Marsh DJ, Hollopeter G, Kafer KE, Palmiter RD (1998) Role of Y5 neuropeptide Y receptor in feeding and obesity. Nat Med 4:718–721
Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (1998) XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY,, and pancreatic polypeptide receptors. Pharmacol Rev 50:143–150
Parker EM, Babij CK, Balasubramaniam A, Burrier RE, Guzzi M, Hamud F, Mukhopadhyay G, Rudinski MS, Tao Z, Tice M, Xia L, Mullins DE, Salisbury BG (1998) GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists. Eur J Pharmacol 349:97–105
Pheng LH, Regoli D (1998) Bioassays for NPY receptors: Old and new. Regul Pept 75–76:79–87
Pheng LH, Quirion R, Iyengar S, Fournier A, Regoli D (1997) The rabbit ileum; A sensitive and selective preparation for the neuropeptide Y Y5 receptor. Eur J Pharmacol 333:R3–R5
Primus RJ, Yevich E, Gallagher DW (1998) In vitro autoradiography of GTP γ[35S] binding at activated NPY receptor subtypes in adult rat brain. Mol Brain Res 58:74–82
Robin-Jagerschmidt C, Sylte I, Bihoreau C, Hendricksen L, Calvet A, Dahl SG, Bénicourt C (1998) The ligand binding site of NPY at the rat Y1 receptor investigated by site-directed mutagenesis and molecular modeling. Mol Cell Endocrinol 139:187–198
Savontaus E, Pesonen U, Rouru J, Huupponen R, Koulu M (1998) Effects of ZD7114, a selective β3-adrenoceptor agonist, on neuroendocrine mechanisms controlling energy balance. Eur J Pharmacol 374:265–274
Wieland HA, Engel W, Eberlein W, Rudolf K, Doods HN (1998) Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br J Pharmacol 125:549–555
Wyss P, Stricker-Krongard A, Brunner L, Miller J, Crossthwaite A, Whitebread S, Criscione L (1998) The pharmacology of neuropeptide Y (NPY) receptor-mediated feeding in rats characterizes better Y5 than Y1, but not Y2 or Y4 subtypes. Regul Pept 75–76:363–371
References
Cai XJ, Widdowson PJ, Harrold J, Wilson S, Buckingham RE, Arch JRS, Tadayyon M, Clapham JC, Wilding J, Williams G (1999) Hypothalamic orexin expression. Modulation by blood glucose and feeding. Diabetes 48:2132–2137
Chen C-T, Hwang L-L, Chang J-K, Dun NJ (2000) Pressor effects of orexins injected intracisternally and to the rostral ventrolateral medulla of anesthetized rats. Am J Physiol 278; Regul Integr Comp Physiol 47:R692–R897
Date Y, Ueta Y, Yamashita H, Yamaguchi H, Matsukura S, Kangawa K, Sakurai T, Yanagisawa M, Nakazato M (1999) Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sci USA 96:748–753
DeLecea L, Sutcliffe JG (1999) The hypocretins/orexins: Novel hypothalamic neuropeptides involved in different physiological systems. Cell Mol Life Sci 56:473–480
Dube MG, Kalra SP, Kalra PS (1999) Food intake elicited by central administration of orexins/hypocretins: Identification of hypothalamic sites of action. Brain Res 842:473–477
Evans ME, Harries M, Patel S, Benham CD (1999) Orexin-A depolarizes neurons in the rat locus coeruleus brain slice in vitro. J Physiol 515:121P
Ida T, Nakahara K, Katayama T, Murakami M, Nakazato M (1999) Effect of lateral cerebroventricular injection of the appetite-stimulating neuropeptide, orexin and neuropeptide Y, on the various behavioral activities of rats. Brain Res 821:526–529
Jain MR, Horvath TL, Kalra PS, Kalra SP (2000) Evidence that NPY Y1 receptors are involved in stimulation of feeding by orexins (hypocretins) in sated rats. Regul Pept 87:19–24
Mondal MS, Nakazato M, Date Y, Murakami N, Yanagisawa M, Matsukura S (1999) Widespread distribution of orexin in the rat brain and its regulation upon fasting. Biochem Biophys Res Commun 256:495–499
Novak KW, Mackowiak P, Switonska MM; Fabis M, Malendowicz LK (2000) Acute orexin effects on insulin secretion in the rat: In vivo and in vitro studies. Life Sci 66:449–454
Parker EM (1999) The role of central neuropeptide, neurotransmitter and hormonal systems in the regulation of body weight. Neurotransmiss 15:3–11
Piper DC, Upton N, Smith MI, Hunter AJ (2000) The novel neuropeptide, orexin A, modulates the sleep-wake cycle of rats. Eur J Neurosci 12:726–730
Pu S, Jain MR, Kalra PS, Kalra SP (1998) Orexins, a novel family of hypothalamic neuropeptides, modulate pituitary luteinizing hormone secretion in an ovarian steroid-dependent manner. Regul Pept 78:133–136
Sakurai T (1999) Orexin and orexin receptors: implication of feeding behavior. Regul Pept 85:25–30
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JRS, Buckingham RB, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu W-S, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M (1998) Orexins and orexin receptors: A family of hypothalamic neuropeptides an G protein-coupled receptors that regulate feeding behavior. Cell 92:573–585
Shirasaka T, Nakazato M, Matsukura S, Takasaki M, Kannan H (1999) Sympathetic and cardiovascular actions of orexins in conscious rats. Am J Physiol 277; Regul Integr Comp Physiol 46:R1780–R1785
Smart D (1999) Orexins: A new family of neuropeptides. Br J Anaesth 83:695–697
Smart D, Jerman JC, Brough SJ, Rushton SL, Murdock PR, Jewitt F, Elshourbagy NA, Ellis JC, Middlemiss DN, Brown F (1999) Characterization of recombinant orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR. Br J Pharmacol 128:1–3
Tamura T, Irahara M, Tezuka M, Kiyokawa M, Aono T (1999) Orexins, orexigenic hypothalamic neuropeptides, suppress the pulsatile secretion of luteinizing hormone in ovarectomized female rats. Biochem Biophys Res Commun 264:759–762
Van den Pol AN, Gao XB, Obrietan K, Kilduff TS, Belousov AB (1999) Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin. J Neurosci 18:7962–7971
Yamada H, Okumura T, Motomura W, Kobayashi Y, Kohgo Y (2000) Inhibition of food intake by central injection of anti-orexin antibody in fasted rats. Biochem Biophys Res Commun 267:527–531
References
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JRS, Buckingham RB, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu W-S, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M (1998) Orexins and orexin receptors: A family of hypothalamic neuropeptides an G protein-coupled receptors that regulate feeding behavior. Cell 92:573–585
Smart D, Jerman JC, Brough SJ, Rushton SL, Murdock PR, Jewitt F, Elshourbagy NA, Ellis JC, Middlemiss DN, Brown F (1999) Characterization of recombinant orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR. Br J Pharmacol 128:1–3
Sullivan E, Tucker EM, Dale IL (1999) Measurement of [Ca2+] using the fluorometric imaging plate reader (FLIRP). In: Lambert DG (ed) Calcium Signaling Protocols. Humana Press, NJ, pp 125–136
Takigawa M, Sakurai T, Kasuya Y, Abe Y, Masaski T, Goto K (1995) Molecular identification of guanine-nucleotide-binding regulatory proteins which couple to endothelin receptors. Eur J Biochem 228:102–108
References
Mondal MS, Nakazato M, Date Y, Murakami N, Handa R, Sakata T, Matsukura S (1999) Characterization of orexin A and orexin B in the microdissected brain nuclei and their contents in two obese rat models. Neurosci Lett 273:45–48
Mitsuma T, Hirooka Y, Kayama M, Mori Y, Yokoi Y, Rhue N, Ping J, Izumi M, Ikai R, Adachi K, Nogimori T (2000) Radioimmunoassay for orexin A. Life Sci 66:897–904
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JRS, Buckingham RB, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu W-S, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M (1998) Orexins and orexin receptors: A family of hypothalamic neuropeptides an G protein-coupled receptors that regulate feeding behavior. Cell 92:573–585
References
Akabayashi A, Koenig JI, Watanabe Y, Alexander JT, Leibowitz SF (1994) Galanin-containing neurons in the paraventricular nucleus: A neurochemical marker for fat ingestion and body weight gain. Proc Natl Acad Sci 91:10375–10379
Ahtaridis SA, Katoch SS, Moreland RS (1998) Mechanism of galanin-induced contraction of longitudinal smooth muscle of the rat jejunum. Am J Physiol 274; Gastrointest Liver Physiol 37:G306–G313
Arletti R, Benelli A, Cavazzuti E, Bertolini A (1997) Galantide improves social memory in rats. Pharmacol Res 35:317–319
Baltazar ET, Kitamura N, Hondo E, Narreto EC, Yamada J (2000) Galanin-like immunoreactive endocrine cells in bovine pancreas. J Anat 196:285–291
Bartfai T, Bedecs K, Land T, Langel Ü, Bertorelli R, Girotti P, Consolo S, Xu X (1991) M-15: High-affinity chimeric peptide that blocks the neuronal actions of galanin in the hippocampus, locus coeruleus, and spinal cord. Proc Natl Acad Sci USA 88:10961–10965
Burazin TCD, Gundlach AL (1998) Inducible galanin and GalR2 receptor system in motor neuron injury and regeneration. J Neurochem 71:879–882
Cai A, Bowers RC, Moore JP Jr., Hyde JF (1998) Function of galanin in the anterior pituitary of estrogen-treated Fischer 344 rats: Autocrine and paracrine regulation of prolactin secretion. Endocrinology 139:2452–2458
Ceresini G, Sgoifo A, Freddi M, Musso E, Parmigiani S, DelRio G, Valenti G (1998) Effects of galanin and the galanin receptor antagonist galantide on plasma catecholamine levels during a psychosocial stress in rats. Neuroendocrinology 67:67–72
Crawley JN, Austin MC, Fiske SM, Martin B, Consolo S, Berthold M, Langel U, Fisone G, Bartfai T (1990) Activity of centrally administered galanin fragments on stimulation of feeding behavior and on galanin receptor binding in the rat hypothalamus. J Neurosci 10:3695–3700
Diaz-Cabiale Z, Narvaez JA, Finnman UB, Bellido I, Ögren SO Fuxe K (2000) Galanin-(1-16) modulates 5-HT1A receptors in the ventral limbic cortex of the rat. NeuroReport 11:515–519
Ekblad E, Håkanson R, Sundler F, Wahlestedt C (1989) Galanin: neuromodulatory and direct contrac tile effects in smooth muscle preparations. Br J Pharmacol 86:241–246
Koshiyama H, Hato Y, Inoue T, Muarkami Y, Yanaihara N, Imura H (1987) Central galanin stimulates pituitary prolactin secretion in rats: possible involvement of hypothalamic vasoactive intestinal polypeptide. Neurosci Lett 7:49–54
Finn PD, Clifton DK, Steiner RA (1998) The regulation of galanin gene expression in gonadotropin-releasing hormone neurons. Mol Cell Endocrinol 140:137–142
Fisone G, Langel U, Carlquist M, Bergman T, Consolo S, Höckfelt T (1989) Galanin receptor and its ligands in the rat hippocampus. Eur J Biochem 181:269–276
Gleason TC, Dreiling JL, Crawley JN (1999) Rat strain differences in response to galanin in the Morris water test. Neuropeptides 33:265–270
Kakuyama H, Mochizuki T, Iguchi K, Yamabe K, Hosoe H, Hoshino M, Yanaihara M (1997) Ala6,D-Tryp8]galanin(1–5)ol is a potent galanin antagonist on insulin release. Biomed Res Japan 18:49–56
Kasa P, Farkas Z, Forgon M, Papp H, Balaspiri L (1998) Effects of different galanins on the release of acetylcholine in the various areas of rat brain. Ann New York Acad Sci 863:435–437
Kask K, Berthold M, Bourne J, Andell S, 'Langel Ü, Bartfai T (1995) Binding and agonist/antagonist actions of M35, galanin(1–13)-bradykinin(2–9)amide chimeric peptide, in Rin m5F insulinoma cells. Regul Rept 59:341–348
Katoh T, Ohmori O (2000) Studies on the total synthesis of Sch 202596, an antagonist of the galanin subtype GalR1: Synthesis of geodin, the spirocoumarone subunit of Sch 202596. Tetrahedron Lett 41:465–469
Kerr BJ, Cafferty WBJ, Gupta YK, Bacon A, Wynick D, McMahon SB, Thompson SWN (2000) Galanin knockout mice reveal nociceptive deficits following peripheral nerve injury. Eur J Neurosci 12:793–802
Kisfalvi I Jr., Burghardt B, Balint A, Zelles T, Vizi ES, Varga G (2000) Antisecretory effects of galanin and its putative antagonists M15, M35, and C7 in the rat stomach. J Physiol Paris 94:37–42
Koegler FH, York DA, Bray GA (1999) The effects on feeding of galanin and M40 when injected into the nucleus of the solitary tract, the lateral parabrachial nucleus, and the third ventricle. Physiol Behav 67:259–267
Korolkiewicz R, Rekowski P, Szyk A, Kato S, Yasuhiro T, Kubomi M, Tashima K, Takeuchi K (1998) Effect of diabetes mellitus on the contractile activity of carbachol and galanin in isolated gastric fundus strips of rats. Pharmacology 57:65–78
Leibowitz SF, Kim T (1992) Impact of a galanin antagonist on exogenous galanin and natural patterns of fat ingestion. Brain Res 599:148–152
Leonharst U, Siegel EG, Köhler H, Barthel M, Tytko A, Nebendahl K, Creutzfeldt W (198) Galanin inhibits glucose-induced insulin release in vitro. Horm Metab Res 21:100–101
Lindskog S, Ahren B, Land T, Langel Ü, Bartfai T (1992) The novel high-affinity antagonist, galantide, blocks the galanin-mediated inhibition of glucose-induced insulin secretion. Eur J Pharmacol 210:183–188
Ma W, Bisby MA (1999) Increase of galanin mRNA in lumbar dorsal root ganglion neurones of adult rats after partial sciatic nerve ligation. Neurosci Lett 262:195–198
McDonald TJ, Dupre J, Tatemoto K, Greenberg GR, Rasziuk J, Mutt V (1985) Galanin inhibits insulin secretion and induces hyperglycemia in dogs. Diabetes 34:192–196
McDonald MP, Crawley JN (1997) Galanin-acetylcholine interactions in rodent memory tasks and Alzheimer's disease. J Psychiatry Neurosci 22:303–317
McDonald MP, Williard LB, Wenk GL, Crawley JN (1998a) Coadministration of galanin antagonist M40 with a muscarinic M1 agonist improves delayed nonmatching to position choice accuracy in rats with cholinergic lesions. J Neurosci 18:5078–5085
McDonald MP, Gleason TC, Robinson JK, Crawley JN (1998b) Galanin inhibits performance on rodent memory tasks. Ann New Acad Sci 863:305–322
Melander T, Hökfelt T, Rökaeus Å (1986) Distribution of galaninlike immunoreactivity in the rat central nervous system. J Comp Neurol 248:475–517
Murakami Y, Kato Y, Koshiyama H, Inoue T, Yanaihara N, Imura H (1987) Galanin stimulates growth hormone (GH) secretion via GH-releasing factor (GRF) in conscious rats. Eur J Pharmacol 136:415–418
Niiro M, Nishimura J; Hirano K, Nakano H, Kanaide H (1998) Mechanism of galanin-induced contraction in the rat myometrium. Br J Pharmacol 124:1623–1632
Nordström Ö, Melander T, Höckfelt T, Bartfai T, Goldstein M (1987) Evidence for an inhibitory effect of the peptide galanin on dopamine release from the rat medial eminence. Neurosci Lett 73:21–26
Ögren SO, Schott PA, Kehr J, Misane T, Razani H (1999) Galanin and learning. Brain Res 848:174–182
Ohtaki T, Kumano S, Ishibashi Y, Ogi K, Matsui H, Harada M, Kitada C, Kurokawa T, Onda H, Fujino M (1999) Isolation and cDNA of a novel galanin-like peptide (GALP) from porcine hypothalamus. J Biol Chem 274:37041–37045
Ottlecz A, Snyder GD, McCann SM (1988) Regulatory role of galanin in control of hypothalamic-anterior pituitary function. Proc Natl Acad Sci USA 85:9861–9865
Park JJ, Baum MJ (1999) Intracerebroventricular infusion of the galanin antagonist M40 attenuates heterosexual partner preference in ferrets. Behav Neurosci 113:391–400
Parker EM (1999) The role of central neuropeptide, neurotransmitter and hormonal systems in the regulation of body weight. Neurotransmiss 15:3–11
Pooga M, Jureus A, Rezaei K, Hasanvan H, Saar K, Kask K, Kjellen P, Land T, Halonen J, Maeorg U, Uri A, Solyom S, Bartfai T, Langel Ü (1998) Novel galanin receptor ligands. J Pept Res 51:65–74
Pramanik A, Ögren SO (1992) Galanin-evoked acetylcholine release in the rat striatum is blocked by the putative galanin antagonist M15. Brain Res 574:317–319
Sahu A, Xu B, Kalra SP (1994) Role of galanin in stimulation of pituitary luteinizing hormone secretion as revealed by a specific receptor antagonist, galantide. Endocrinology 134:529–536
Skofitsch G, Jacobowitz DM (1985) Immunohistochemical mapping of galanin-like neurons in the rat central nervous system. Peptides 6:509–546
Tatemoto K, Rökaeus Å, Jörnvall H, McDonald TJ, Mutt V (1983) Galanin, a novel biologically active peptide from porcine intestine. FEBS Lett 164:124–128
Todd JF, Small CJ, Akinsanya KO, Stanley SA, Smith DM, Bloom SR (1998) Galanin is a paracrine inhibitor of gonadotroph function in the female rat. Endocrinology 139:4222–4229
Tsuda K, Yokoo H, Goldstein M (1989) Neuropeptide Y and galanin in norepinephrine release in hypothalamic slices. Hypertension 14:81–86
Wang J, Akabayashi A, Hi J-Y, Dourmashkin J, Alexander JT, Silva I, Lighter J, Leibowitz SF (1998) Hypothalamic galanin: Control by signals from fat metabolism Brain Res 804:7–20
Wang D, Lundeberg T, Yu L-C (2000) Antinociceptive role of galanin in periaqueductal grey of rats with experimentally induced mononeuropathy. Neuroscience 96:767–771
Wynick D, Small CJ, Bacon A, Holmes FE, Norman M, Ormandy CJ, Kilic E, Kerr NCH, Ghatei M, Talamantes F, Bloom SR, Pachnis V (1998) Galanin regulates prolactin release and lactotroph proliferation. Proc Natl Acad Sci USA 95:12671–12676
Xu X-J, Wiesenfeld-Hallin Z, Langel Ü, Bedecs K, Bartfai T (1995) New high affinity peptide antagonists to the spinal galanin receptor. Br J Pharmacol 116:2076–2080
Xu X-J, Andell S, Bartfai T, Wiesenfeld-Hallin Z (1996) Fragments of the galanin message-associated peptide (GMAP) modulate the spinal reflex in rat. Eur J Pharmacol 318:301–306
Yu L-C, Lundeberg S, An H, Wang F-X, Lundeberg T (1999) Effects of intrathecal galanin on nociceptive response in rats with mononeuropathy. Life Sci 64:1145–1153
Zachariou V, Parikh K, Picciotto MR (1999) Centrally administered galanin blocks morphine place preference in the mouse. Brain Res 831:33–42
References
Ahmad S, O'Donnell D, Payza K, Ducharma J, Menard D, Brown W, Schmidt R, Wahlestedt C, Shen SH, Walker P (1998) Cloning and evaluation of the role of rat GALR-2, a novel subtype of galanin receptor, on the control of pain reception. Ann New York Acad Sci 863:108–119
Bloomquist BT, Beauchamp MR, Zhelnin L, Brown SE, Gore-Willse AR, Gregor P, Cornfield LJ (1998) Cloning and expression of the human galanin receptor GalR2. Biochem Biophys Res Commun 243:474–479
Branchek TA, Smith KE, Gerald C, Walker MW (2000) Galanin receptor subtypes. Trends Pharmacol Sci 21:109–116
Fathi Z, Battaglino PM, Iben LG, Li H, Baker E, Zhang D, McGovern R, Lahle CD, Sutherland GR, Iismaa TP, Dickinson KEJ, Antal-Zimanyi I (1998) Molecular characterization, pharmacological properties and chromosomal localization of the human GALR2 receptor. Mol Brain Res 58:156–169
Habert-Ortoli E, Aminranoff B, Loquet I, Laburthe M, Mayaux JF (1994) Molecular cloning of a functional human galanin receptor. Proc Natl Acad Sci USA 91:9780–9783
Kolakowski LF Jr., O'Neill GP, Howard AD, Broussard SR, Sullivan KA, Feighner SD, Sawzdargo M, Nguyen T, Kargman S, Shiao L-L, Hreniuk DL, Tan CP, Evans J, Abramovitz M, Chateauneuf A, Coulombe N, Ng G, Johnson MP, Tharian A, Khoshbouei H, George SR, Smith RG, O'Dowd BF (1998) Molecular characterization and expression of cloned human galanin receptors GALR2 and GALR3. J Neurochem 71:2239–2251
Lee DK, Nguyen T, O'Neill GP, Cheng R, Liu Y, Howard AD, Coulombe N, Tan CP, Tang-Nguyen AT, George SR, O'Dowd BF (1999) Discovery of a receptor related to the galanin receptors. FEBS Lett 446:103–107
Pang L, Hashemi T, Lee-H JJ, Maguire M, Graziano MP; Bayne M, Hawes B, Wong G, Wang S (1998) The mouse GalR2 receptor: Genomic organization, cDNA cloning, and functional characterization. J Neurochem 71:2252–2259
Parker EM, Izzarelli DG, Nowak HP, Mahle CD, Iben LG, Wang J, Goldstein ME (1995) Cloning and characterization of the rat GALR1 galanin receptor from Rin14B insulinoma cells. Mol Brain Res 34:179–189
Saar K, Valkna A, Soomets U, Rezaei K, Zorko M, Zilmer M, Langel Ü (1997) Role of the third cytoplasmatic loop in signal transduction by galanin receptors. Biochem Soc Transact 25:1036–1040
Smith KE, Walker MW, Artymyshyn R, Bard J, Borowsky B, Tamm JA, Yoa W-J, Vaysse PJ-J, Brancheck TA, Walker MW, Jones KA (1998) Cloned human and rat GAL3 receptors: Pharmacology and activation of G-protein inwardly rectifying K+ channels. J Biol Chem 273:23321–23326
Sullivan KA, Shiao L-L, Cascieri MA (1997) Pharmacological characterization and tissue distribution of the human and rat GALR1 receptors. Biochem Biophys Res Commun 233:823–828
Wang S, Parker EM (1998) Galanin receptor subtypes as potential therapeutic targets. Expert Opin Ther Pat 8:1225–1235
Wang S, Hashemi T, He C, Strader C, Bayne M (1997) Molecular cloning and pharmacological characterization of a new galanin receptor subtype. Mol Pharmacol 52:337–343
References
Ahima RS, Flier JS (2000) Adipose tissue as an endocrine organ. Trends Endocrin Metab 11:327–332
Antras J, Lasnier F, Pairault J (1991) Adipsin gene expression in 3T3-F442A adipocytes is posttranscriptionally down-regulated by retinoic acid. J Biol Chem 266:1157–1161
Choy LN, Rosen BS, Spiegelman BM (1992) Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem 267:12736–12741
Cianflone K, Maslowska M, Sniderman AD (1999) Acylation stimulating protein (ASP) an adipocyte autocrine: new directions. Sem Cell Dev Biol 10:31–34
Cook KS, Min HY, Johnson D, Chaplinsky RJ, Flier JS, Hunt CR, Spiegelman BM (1987) Adipsin: a circulating serine protease homologue secreted by adipose tissue and sciatic nerve. Science 237:402–405
Dugail I, Quignard-Boulange A, le Liepvre X, Lavau M (1990) Impairment of adipsin expression is secondary to the onset of obesity in db/db mice. J Biol Chem 265:1831–1833
Flier JS, Cook KS, Usher P, Spiegelman BM (1987) Severely impaired adipsin expression in genetic and acquired obesity. Science 237:405–408
Johnson PA, Greenwood MRC, Horwitz BA, Stern JS (1991) Animal models of obesity: Genetic aspects. Annu Rev Nutr 11:325–352
Kitagawa K, Rosen SB, Spiegelman BM, Lienhard GE, Tanner LI (1998) Insulin stimulates acute release of adipsin from 3T3-L1 adipocytes. Biochem Biophys Acta 1014:83–89
Lwell BB, Flier JS (1990) Differentiation dependent biphasic regulation of adipsin gene expression by insulin and insulin-like growth factor-1 in 3T3-F442A adipocytes. Endocrinology 127:2898–2906
Lowell BB, Napolitano A, Usher P, Dulloo AG, Rosen BS, Spiegelman BM, Flier JS (1990) Reduced adipsin expression in murine obesity: effect of age and treatment with the sympathomimetic-thermogenic drug mixture ephedrine and caffeine. Endocrinology 126:1514–1520
Miner JL, Byatt CA, Baile CA, Krivi GG (1993) Adipsin expression and growth rate in rats as influenced by insulin and somatotropin. Physiol Behav 54:207–212
Murray I, Sniderman AD, Cianflone K (1999) Enhanced triglyceride clearance with intraperitoneal human acylation stimulating protein in C5BL/6 mice. Am J Physiol 277:E474–E480
Murray I, Havel PJ, Sniderman AD, Cianflone K (2000) Reduced body weight, adipose tissue, and leptin levels despite increased energy intake in female mice lacking acylation-stimulating protein. Endocrinology 141:1041–1049
Moustaid N, Lasnier F, Hainque B, Quignard-Boulange A, Pairault J (1990) Analysis of gene expression during adipogenesis in 3T3-F442A preadipocytes: insulin and dexamethasone control. J Cell Biochem 42:243–254
Napolitano A, Lowell BB, Damm D, Leibel RL, Ravussin E, Jimerson DC, Lesem MD, Van Dyke DC, Daly PA, Chatis P (1994) Concentrations of adipsin in blood and rates of adipsin secretion by adipose tissue in humans with normal, elevated and diminished adipose tissue mass. Int J Obes Relat Metab Disord 18:213–218
Peake PW, O'Grady S, Pussell BA, Charlesworth JA (1997) Detection and quantification of the control proteins of the alternative pathway of complement in 3T3-L1 adipocytes. Eur J Clin Invest 27:922–927
Rosen BS, Cook KS, Yaglom J, Groves DL, Volanikis JE, Damm D, White T, Spiegelman BM (1989) Adipsin and complement factor D activity: an immune-related defect in obesity. Science 23:1483–1487
Shillabeer G, Hornford J, Forden JM, Wong NC, Russell JC, Lau DC (1992) Fatty acid synthase and adipsin mRNA levels in obese and lean JCR:LAS-cp rats: effect of diet. J Lipid Res 33:31–39
Sniderman AD, Cianflone K (1994) The adipsin-ASP pathway and regulation of adipocyte function. Ann Med 26:388–393
Spiegelman BM, Lowell B, Napolitano A, Dubuc P, Barton D, Francke U, Groves DL, Cook KS, Flier JS (1989) Adrenal glucocorticoids regulate adipisin gene expression in genetically obese mice. J Biol Chem 264:1811–1815
Spurlock ME, Hahn KJ, Miner JL (1996) Regulation of adipsin and body composition in the monosodium glutamate (MSG)-treated mouse. Physiol Behav 60:1217–1221
Takahashi M, Arita Y, Yamagata K, Matsukawa Y, Okutomi K, Horie M, Shimomura I, Hotta K, Kuriyama H, Kihara S, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y (2000) Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obese Relat Metab Disord 24:861–868
Van Harmelen V, Reynisdottir S, Cianflone K, Degerman E, Hoffstedt J, Nisell K, Sniderman A, Arner P (1999) Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J Biol Chem 274:18243–18251
White RT, Damm D, Hancock N, Rosen BS, Lowell BE, Usher P, Flier S, Spiegelman BM (1992) Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J Biol Chem 267:9210–9213
References
Dugail I, Le Liepvre X, Quignard-Boulangé A, Pairault J, Lavau M (1989) Adipsin mRNA amounts are not decreased in the genetically obese Zucker rat. Biochem J 257:917–919
Dugail I, Quignard-Boulangé A, Le Liepvre X, Lavau M (1990) Impairment of adipsin gene expression is secondary to the onset of obesity in db/db mice. J Biol Chem 265:1831–1833
Flier JS, Cook KS, Usher P, Spiegelman BM (1987) Severely impaired adipsin expression in genetic and acquired obesity. Science 237:405–408
Lowell BB, Napolitano A, Usher P, Dulloo AG, Rosen BS, Spiegelman BM, Flier JS (1990) Reduced adipsin expression in murine obesity: Effect of age and treatment with the sympathomimetic-thermogenic drug mixture ephedrine and caffeine. Endocrinology 126:1514–1520
Miner JL, Byatt JC, Baile CA, Krivi GG (1993) Adipsin gene expression and growth in rats as influenced by insulin and somatotropin. Physiol Behav 54:207–212
Napolitano A, Lowell BB, Damm D, Leibel RL, Ravussin E, Jimerson DC, Lesem MD, Van Dyke DC, Daly PA, Chatis P, White RL, Spiegelman BM, Flier JS (1994) Concentrations of adipsin in blood and rates of adipsin secretion by adipose tissue in humans with normal, elevated and diminished adipose tissue mass. Intern J Obesity 18:213–218
Platt KA, Claffey KP, Wilkison WO, Spiegelman BM, Ross SR (1994) Independent regulation of adipose tissue specificity and obese response of the adipsin promoter in transgenic mice. J Biol Chem 269:28558–28562
Spiegelman BM, Lowell B, Napolitano A, Dubuc P, Barton D, Francke U, Groves DL, Cook KS, Flier JS (1989) Adrenal glucocorticoids regulate adipsin gene expression in obese mice. J Biol Chem 264:1811–1815
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag
About this entry
Cite this entry
Vogel, H.G., Vogel, W.H., Schölkens, B.A., Sandow, J., Müller, G., Vogel, W.F. (2002). Anti-obesity activity1 . In: Vogel, H.G., Vogel, W.H., Schölkens, B.A., Sandow, J., Müller, G., Vogel, W.F. (eds) Drug Discovery and Evaluation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-29837-1_13
Download citation
DOI: https://doi.org/10.1007/3-540-29837-1_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-42396-6
Online ISBN: 978-3-540-29837-3
eBook Packages: Springer Book Archive